Label	Predicted function	Activity present in the following species	Activity suspected in T. maritimum

Iron uptake

MARIT_0169-0174	Siderophore biosynthesis system, Tbs	Deep sea metagenome (Fujita et al., 2012)	Avendaño-Herrera et al., 2005b

MARIT_1312-1313	Heme uptake mechanism, HmuYR	Porphyromonas gingivalis (Olczak et al., 2008; Wójtowicz et al., 2009)	Avendaño-Herrera et al., 2005b

MARIT_0141 – 0142	Fe2+ uptake system, FeoAB	Porphyromonas gingivalis (Lau et al., 2016)	Avendaño-Herrera et al., 2005b

MARIT_1664	Iron acquisition, uptake or storage, imelysin family protein	Synechococcus elongatus (Xu et al., 2011)	Avendaño-Herrera et al., 2005b

MARIT_1661	Iron acquisition, uptake or storage, imelysin family protein	Synechococcus elongatus (Xu et al., 2011)	Avendaño-Herrera et al., 2005b

Stress resistance

MARIT_3105	Superoxide dismutase [Mn/Fe], SodA	Staphylococcus carnosus (Barrière et al., 2001)	Suzuki et al., 2001

MARIT_1670	Superoxide dismutase [Fe], SodB	Legionella pneumophila (Amemura-Maekawa et al., 1996)	Suzuki et al., 2001

MARIT_1821	Superoxide dismutase [Cu–Zn], SodC	Schistosoma mansoni (da Silva et al., 1992)	Suzuki et al., 2001

MARIT_0946	KatG catalase	Geobacillus stearothermophilus (Singh et al., 2008)	Suzuki et al., 2001

MARIT_2408	KatA catalase	Pseudomonas aeruginosa (Brown et al., 1995)	Suzuki et al., 2001

Toxins

MARIT_0124	Cholesterol-dependent cytolysin	Capnocytophaga canimorsus (Gilbert, 2010)	Baxa et al., 1988

MARIT_1085	Collagenase	Cytophaga sp. (Sasagawa et al., 1995)	Baxa et al., 1988

MARIT_1748	Sphingomyelinase	Bacillus cereus (Oda et al., 2010)

MARIT_2033	Ceramidase	Pseudomonas aeruginosa (Ito et al., 2014)

MARIT_2107	Chondroitin AC lyase	Flavobacterium columnare (Suomalainen et al., 2006)	Rahman et al., 2014

MARIT_2328	Streptopain family protease	Streptococcus pyogenes (Nelson et al., 2011)	Wakabayashi et al., 1986; Baxa et al., 1988

MARIT_2678 - 2687	Sialoglycan degradation and uptake	Capnocytophaga canimorsus (Mally et al., 2008)

Lab	Predicted fun	Activity present in the follow	A

el	ction	ing species	ctivity suspected in T. maritimum

Iron uptake

MARIT_0169-0174	Siderophore biosynthesis system, Tbs	Deep sea metagenome (Fujita et al., 2012)	Avendaño-Herrera et al., 2005b

MARIT_1312-1313	Heme uptake mechanism, HmuYR	Porphyromonas gingivalis (Olczak et al., 2008; Wójtowicz et al., 2009)	Avendaño-Herrera et al., 2005b

MARIT_0141 – 0142	Fe2+ uptake system, FeoAB	Porphyromonas gingivalis (Lau et al., 2016)	Avendaño-Herrera et al., 2005b

MARIT_1664	Iron acquisition, uptake or storage, imelysin family protein	Synechococcus elongatus (Xu et al., 2011)	Avendaño-Herrera et al., 2005b

MARIT_1661	Iron acquisition, uptake or storage, imelysin family protein	Synechococcus elongatus (Xu et al., 2011)	Avendaño-Herrera et al., 2005b

Stress resistance

MARIT_3105	Superoxide dismutase [Mn/Fe], SodA	Staphylococcus carnosus (Barrière et al., 2001)	Suzuki et al., 2001

MARIT_1670	Superoxide dismutase [Fe], SodB	Legionella pneumophila (Amemura-Maekawa et al., 1996)	Suzuki et al., 2001

MARIT_1821	Superoxide dismutase [Cu–Zn], SodC	Schistosoma mansoni (da Silva et al., 1992)	Suzuki et al., 2001

MARIT_0946	KatG catalase	Geobacillus stearothermophilus (Singh et al., 2008)	Suzuki et al., 2001

MARIT_2408	KatA catalase	Pseudomonas aeruginosa (Brown et al., 1995)	Suzuki et al., 2001

Toxins

MARIT_0124	Cholesterol-dependent cytolysin	Capnocytophaga canimorsus (Gilbert, 2010)	Baxa et al., 1988

MARIT_1085	Collagenase	Cytophaga sp. (Sasagawa et al., 1995)	Baxa et al., 1988

MARIT_1748	Sphingomyelinase	Bacillus cereus (Oda et al., 2010)

MARIT_2033	Ceramidase	Pseudomonas aeruginosa (Ito et al., 2014)

MARIT_2107	Chondroitin AC lyase	Flavobacterium columnare (Suomalainen et al., 2006)	Rahman et al., 2014

MARIT_2328	Streptopain family protease	Streptococcus pyogenes (Nelson et al., 2011)	Wakabayashi et al., 1986; Baxa et al., 1988

MARIT_2678 - 2687	Sialoglycan degradation and uptake	Capnocytophaga canimorsus (Mally et al., 2008)


Sample items	%Agree

I am worried that other people might realize that I am HIV + if they see me taking my HIV medications.	52

I get frustrated taking my HIV medications because I have to plan my life around them.	40

I don’t like taking my HIV medications because they remind me that I am HIV + .	40

I feel that my healthcare provider takes my needs into account when making recommendations about which HIV medications to take.	84

Most people who are important to me who know I’m HIV positive support me in taking my HIV medications.	88

My healthcare provider doesn’t give me enough support when it comes to taking my medications as prescribed.	24

It frustrates me to think that I will have to take these HIV medications every day for the rest of my life.	44

I am worried that the HIV medications I have been prescribed will hurt my health.	56

It upsets me that the HIV medications I have been prescribed can affect the way I look.	52

It upsets me that the HIV medications I have been prescribed can cause side effects.	64


Smoking habit	Frequency among patients	Percentage	95% Confidence interval

No	106	77.9	70.1-84.2

Yes	27	19.9	13.9-27.5

Unknown	3	2.2	0.7-6.7


		No/minimal impairment(independent)	Moderate impairment(independent/unilateral support)	Severe impairment(bilateral support/wheelchair)	p value

Peroneal nerve

Motor CV (m/sec)	CIDP	40.4 ± 1.3	26.7 ± 14.7a	21.0 ± 13.4	0.006

MMN	40.7 ± 6.8	37.2 ± 5.5	33.9 ± 3.1	0.099

CMAP amplitude (mV)	CIDP	4.4 ± 3.0	1.7 ± 1.4a	0.1 ± 0.2	0.016

MMN	3.1 ± 2.1	2.8 ± 1.8	1.1 ± 1.2	0.110

CSA popliteal fossa (mm2)	CIDP	12.2 ± 3.1	17.9 ± 3.5a	16.7 ± 2.0	0.045

MMN	10.5 ± 1.5	17.3 ± 4.3	14.0 ± 1.9	0.114

CSA fibular head (mm2)	CIDP	8.8 ± 1.7	11.5 ± 3.0	11 ± 1.3	0.227


	Mean (standard deviation)	Min value	Max value

CGI-S	4.16 (0.92)	2	6

PANSS total score	79.4 (16.34)	45	140

PANSS positive score	16.46 (5.15)	7	33

PANSS negative score	23.19 (5.68)	10	43

PANSS general score	39.75 (9.77)	18	76

V-SIR	24.32 (7.82)	9.4	49.19

SCD total score	7.6 (4.1)	0	18

	Mean (standard deviation)	Min value	Max value

SCD total score	7.6 (4.1)	0	18


Features	Patients

n	Frequency %

Gender

 Males	344	82.3

 Females	74	17.7

Age (years)

 Min	31

 Max	93

 Mean ± SD	 	66.7 ± 10.9

 Median	67

Smoking

 Smokers	283	67.7

 Nonsmokers	117	28.0

 Not specified	18	4.3

Tumor stages

 TIS	1	0.2

 Ta	91	21.8

 T1	198	47.4

 T2	72	17.2

 T3	27	6.5

 T4	27	6.5

 Not specified	2	0.4

Tumor grades

 1973

CIS	1	0.2

G1	139	33.3

G2	186	44.5

G3	86	20.6

Not specified	6	1.4

 2004

PUNLMP	11	2.6

CIS	1	0.2

Low	241	57.7

High	156	37.3

Not specified	9	2.2

Recurrence

 No	268	64.1

 Yes	150	35.9

Features	Patients

n	Frequency %

Gender

Males	344	82.3

Females	74	17.7

Age (years)

Min	31

Max	93

Mean ± SD		66.7 ± 10.9

Median	67

Smoking

Smokers	283	67.7

Nonsmokers	117	28.0

Not specified	18	4.3

Tumor stages

TIS	1	0.2

Ta	91	21.8

T1	198	47.4

T2	72	17.2

T3	27	6.5

T4	27	6.5

Not specified	2	0.4

Tumor grades

1973

CIS	1	0.2

G1	139	33.3

G	186


Groups	Ovarian weight

mg	mg/g body weight


	Final grade

	Grade	1	2	3

Predicted grade	1	21	0	0

	2	5	35	9

	3	1	6	7

	1 or 2	7	1	1

	2 or 3	0	2	8

	Not predicted	1	1	0


	Nurse/midwives n = 13	Doctors n = 05	Administrators n = 06

Age (years)

<30	6	1	0

30-39	3	3	0

40-49	2	0	1

≥50	2	1	5

Marital status

Single	1	0	0

Married	12	5	6

Widowed	0	0	0

Gender

Female	13	0	0

Male	0	5	6

Years of experience

0-4	5	2	1

5-9	5	2	0

10-15	1	0	0

15+	2	1	5

Hospital location

Urban	8	4	3

Peri-urban	5	1	3

	Nurse/midwives n = 13	Doctors n = 05	Administrators n = 06

-4	5	2	1

5-9	5	2	0

10-15	1	0	0

15+	2	1	5

Hospital location

Urban	8	4	3

Peri-urban	5	1	3


	Total	N/100 orders	N/100 admissions	N/1000 patient-days

Orders	4942	NA*	7844	9709

Medication error	492	10	780	967

Adverse drug events	8	0.16	12.6	15.7

Potential adverse drug events	113	2.28	179.3	222

	Total	N/100 orders	N/100 admissions	N/1000 patient-days

Order	494	N		9709

	Total	N/100 orders	N/100 admissions	N/1000 patient-days

s	2	A*	7844

Medication error	492	10	780	967

Adverse drug events	8	0.16	12.6	15.7

Potential adverse drug events	113	2.28	179.3	222


Parameters	Value

Plant life	30 years

Discount rate	10%

Financing	40% equity

Loan terms	10-year loan at 8% APR

General plant depreciation	200% declining balancea

General plant recovery period	7 years

Steam plant depreciation	150% declining balance

Steam plant recovery period	20 years

Construction period	3 years

0-12 months	8% of project cost

12-24 months	60% of project cost

24-36 months	32% of project cost

Working capital	5% of fixed capital investment

Start-up time	3 months

Revenues during start-up	50%

Variable costs incurred during start-up	75%

Fixed costs incurred during start-up	100%


 Patient characteristics

Male/female	49 (63.6%)/28 (36.4%)

Birth weight (gr)	2930 ± 485 (range 4300-1800)

Gestational age at delivery (wk)	37 ± 2 (range 42–32)

Term/preterm delivery	40 (52%)/37 (48%)

Left/right side	67 (87%)/10 (13%)

Inborn/outborn	71 (92.2%)/6 (7.8%)

Prenatal diagnosis	68 (88.3%)

Associated anomalies	18 (23.4%)

Associated congenital heart diseases	4 (5.2%)

Patient characteristics

Male/female	49 (63.6%)/28 (36.4%)

Birth	2930

Patient characteristics

 weight (gr)	 ± 485 (range 4300-1800)

Gestational age at delivery (wk)	37 ± 2 (range 42–32)

Term/preterm delivery	40 (52%)/37 (48%)

Left/right side	67 (87%)/10 (13%)

Inborn/outborn	71 (92.2%)/6 (7.8%)

Prenatal diagnosis	68 (88.3%)

Associated anomalies	18 (23.4%)

Associated congenital heart diseases	4 (5.2%)


date (day of chth)

(I day)	1.	Doxorubicin 80 mg i.v.

	2.	Cis-Platinium 40 mg i.v.

	3.	5-FU 800 mg i.v.

	4.	Roferon 9 MU

(II day)	1.	Cis-Platinium 40 mg i.v.

	2.	5-FU 800 mg i.v.

	3.	Roferon 9 M U

(III day)	1.	Cis-Platinium 40 mg i.v.

	2.	5-FU 800 mg i.v.

	3.	Roferon 9 M U

(IV day)	1.	Cis-Platinium 40 mg i.v.

	2.	5-FU 800 mg i.v.

	3.	Roferon 9 M U

Doxorubicin 80 mg i.v.

Cis-Platinium 40 mg i.v.

5-FU 800 mg i.v.

Roferon 9 MU

Cis-Platinium 40 mg i.v.

5-FU 800 mg i.v.

Roferon 9 M U

Cis-Platinium 40 mg i.v.

5-FU 800 mg i.v.

Roferon 9 M U

Cis-Platinium 40 mg i.v.

5-FU 800 mg i.v.

Roferon 9 M U


Characteristics	mRNA profiling	microRNA profiling	Total subjects

Trisomy 21 (n = 3)	Normal (n = 5)	P value	Trisomy 21 (n = 4)	Normal (n = 5)	P value	Trisomy 21 (n = 7)	Normal (n = 10)	P value

Maternal Age (years)	34.6 ± 3.8	37.4 ± 3.9	0.853	30.3 ± 2.2	34.2 ± 3.1	0.628	32.1 ± 3.6	35.8 ± 3.7	0.062

Gestational age (weeks)	12.0 ± 0.0	12.2 ± 0.4	0.092	12.2 ± 0.4	12.4 ± 0.7	0.071	12.1 ± 0.4	12.3 ± 0.6	0.454


Characteristics	Patients

Median age (y) (range)	52 (36–76)

Median parity (range)	3 (0–9)

Median BMI (range)	31.2 (21.4–41.5)

Prior surgery for prolapse including hysterectomy (n, %) 	3 (15)

Prior hysterectomy for benign tumor (n, %)	4 (20)

Stage of prolapse

  Stage II (n, %)	6 (30)

  Stage III (n, %)	12 (60)

  Stage IV (n, %)	2 (10)

Urinary incontinence (n, %)	16 (80)


Sources of Attrition	N (%)	AAa (%)	EAa (%)	p-valuec,d


Activities	Advantages	Specific challenges	Response

School meetings	• Easy to organize	• Low attendance	• Follow-up school meetings organized

• Resource and time efficient	• Consenting decisions may be influenced by other parents	• Meetings held outside classrooms to minimize disruption

• Follow-up consent meetings allowed time for consultations	• Disruption to school schedules	• Insistence on parental consent

 	• Danger of proxy consent from relatives	• Household visits

Household visits	• Allows for more in-depth and one-on-one discussions of the study	• Difficulties in tracking households	• Use of village elders/community health workers to track parents

• Eliminates pressure and influence associated with school meetings	• Unavailability of parents at home	• Field workers sent to households early in the morning or late in the evening

• Can allow joint decision-making to participate in research	• Time consuming

 	• Resource intensive


Fluorescent real-time PCR	Orientation	Sequencea (5'---3')	Amplicon length (bp)

TaqMan	Sense	CCGCCTTTGAGTGAGCTGATA	210

	Anti-sense	TGTAGACAACATCCCCTCCCC

	Probe	FAM CGCCGCAGCCGAACGACCGAG TAMRA

	Sense	GTATTACCGCCTTTGAGTGAGCT	510

	Anti-sense	ATGACAATCAGCTACTTCACTGTTG

	Probe	FAM CGCCGCAGCCGAACGACCGAG TAMRA

	Sense	CCGCCTTTGAGTGAGCTGATA	992

	Anti-sense	CTCCGCTGGTCCGATTGAAC

	Probe	FAM CGCCGCAGCCGAACGACCGAG TAMRA

	Sense	CCGCCTTTGAGTGAGCTGATA	1596

	Anti-sense	AATGGTTTCTGACGTATGTGCTTAG

	Probe	FAM CGCCGCAGCCGAACGACCGAG TAMRA

UTa	Sense	taggaacaggcggcgacgaATACAA CATCCGCTTGCCCTCATC	195

	Anti-sense	TGCCAAAGGGTTCGTGTAG

	Sense	taggaacaggcggcgacga ATACAA CATCCGCTTGCCCTCATC	546

	Anti-sense	GGGATAACGCAGGAAAGAACAT

	Sense	CAGACGTGAAACCCAACATACC	1032

	Anti-sense	Taggaacaggcggcgacga ATACAA CCCAATAGCAGCCAGTCCCT

	Sense	taggaacaggcggcgacga ATACAA TCTGCTGTAGTGAGTGGGTTGC	1630

	Anti-sense	GCCGATTGTCTGTTGTGCC

	UT probe	FAM TCGTCGCCGCCTGTTCCTA TAMRA

AUDP probeb	Sense	taggaacaggcggcgacgagcgtgggacataAAACTCCATCCGCTTGCCCTCATC	195

	Anti-sense	TGCCAAAGGGTTCGTGTAG

	Sense	taggaacaggcggcgacgagcgtgggacataAAACTCCATCCGCTTGCCCTCATC	546

	Anti-sense	GGGATAACGCAGGAAAGAACAT

	Sense	CAGACGTGAAACCCAACATACC	1032

	Anti-sense	taggaacaggcggcgacgagcgtgggacataAAACTCCCCAATAGCAGCCAGTCCCT

	Sense	taggaacaggcggcgacgagcgtgggacataAAACCTCTCTGCTGTAGTGAGTGGGTTGC	1630

	Anti-sense	GCCGATTGTCTGTTGTGCC

	FP	FAM TAGGAACAGGCGGCGACGAGCGTGGGACATA

	QP	AGTCGTCGCCGCCTGTTCCTA Dabcyl

Fluorescent real-time PCR	Orientation	Sequencea (5'---3')	Amplicon length (bp)

	Anti-sense	AATGGTTTCTGACGTATGTGCTTAG

	Probe	FAM CGCCGCAGCCGAACGACCGAG TAMRA

UTa	Sense	taggaacaggcggcgacgaATACAA CATCCGCTTGCCCTCATC	195

	Anti-sense	TGCCAAAGGGTTCGTGTAG

	Sense	taggaacaggcggcgacga ATACAA CATCCGCTTGCCCTCATC	546

	Anti-sense	GGGATAACGCAGGAAAGAACAT

	Sense	CAGACGTGAAACCCAACATACC	1032

	Anti-sense	Taggaacaggcggcgacga ATACAA CCCAATAGCAGCCAGTCCCT

	Sense	taggaacaggcggcgacga ATACAA TCTGCTGTAGTGAGTGGGTTGC	1630

	Anti-sense	GCCGATTGTCTGTTGTGCC

	UT probe	FAM TCGTCGCCGCCTGTTCCTA TAMRA

AUDP probeb	Sense	taggaacaggcggcgacgagcgtgggacataAAACTCCATCCGCTTGCCCTCATC	195

	Anti-sense	TGCCAAAGGGTTCGTGTAG

	Sense	taggaacaggcggcgacgagcgtgggacataAAACTCCATCCGCTTGCCCTCATC	546

	Anti-sense	GGGATAACGCAGGAAAGAACAT

	Sense	CAGACGTGAAACCCAACATACC	1032

	Anti-sense	taggaacaggcggcgacgagcgtgggacataAAACTCCCCAATAGCAGCCAGTCCCT

	Sense	taggaacaggcggcgacgagcgtgggacataAAACCTCTCTGCTGTAGTGAGTGGGTTGC	1630

	Anti-sense	GCCGATTGTCTGTTGTGCC

	FP	FAM TAGGAACAGGCGGCGACGAGCGTGGGACATA

	QP	AGTCGTCGCCGCCTGTTCCTA Dabcyl


Variables	Univariate analysis

HR	95% CI	P

Age (< 65 vs. ≥65)	1.47	0.68–3.17	NS

Gender (female vs. male)	0.74	0.29–1.84	NS

Stage (I vs. II vs. III)	1.64	1.00–2.69	0.049

Histology (adeno vs. other)	1.50	0.69–3.27	NS

Lymph node status (negative vs. positive)	2.09	0.95–4.60	NS

pT status (pT1a-2b vs. pT3–4)	2.65	1.25–5.62	0.011

Differentiation (poor vs. well-moderate)	0.80	0.37–1.75	NS

Smoking (smokers vs. nonsmokers)	0.48	0.18–1.23	NS

COPD (present vs. absent)	1.17	0.54–2.55	NS

M1 macrophages in islets (high vs. low)	2.83	1.20–6.68	0.017

M1 macrophages in stroma (high vs. low)	1.91	0.86–4.25	NS

Total M1 macrophages (high vs. low)	1.43	0.63–3.21	NS

M2 macrophages in islets (high vs. low)	1.43	0.66–1.43	NS

M2 macrophages in stroma (high vs. low)	1.00	0.73–1.37	NS

Total M2 macrophages (high vs. low)	0.31	0.13–0.75	0.009

IL-10	0.74	0.35–1.55	NS

TNF-α	1.16	0.55–2.45	NS

IFN-γ	0.67	0.31–1.43	NS

Variables	Univariate analysis

HR	95% CI	P

Total M1 macrophages (high vs. low)	1.43	0.63–3.21	NS

M2 macrophages in islets (high vs. low)	1.43	0.66–1.43	NS

M2 macrophages in stroma (high vs. low)	1.00	0.73–1.37	NS

Total M2 macrophages (high vs. low)	0.31	0.13–0.75	0.009

IL-10	0.74	0.35–1.55	NS

TNF-α	1.16	0.55–2.45	NS

IFN-γ	0.67	0.31–1.43	NS


Gender	male

	female

Age	per year

pT	1

	2

	3

	4

pN	0

	1

	2

	3

CD3i	high

	low

Gender	male

	female

Age	per year

pT	1

	2

	3

	4

pN	0

	1

	2

	3

CD3i	diffuse

Distribution	focal

Gender	male

	female

Age	per year

pT	1

	2

	3

	4

pN	0

	1

	2

	3

PD-L1 TCs	high

	low


Characteristics (Total n = 126)

Maternal

Age, year	32.8 ± 5.0

Ethnicity

European	104 (83%)

Maori	8 (6%)

Pacific	1 (1%)

Other	13 (10%)

Skin color 2

Very light	67 (53%)

Light	51 (41%)

Intermediate	5 (4%)

Dark	3 (2%)

Primiparous	37 (29%)

Tertiary education 3	90 (71%)

Pre-pregnancy BMI, kg/m2 Primiparous	25.0 ± 6.2

Smoker	9 (7%)

Antenatal vitamin D supplement use 4	35 (28%)

Supplement intake IU/day 4

Consumers only	339 ± 269

Infant

Gestation, week	39.3 ± 1.1

Gender, male	61 (48%)

Birth weight, g	3506 ± 495

Birth Season

Spring	30 (24%)

Summer	28 (22%)

Autumn	28 (22%)

Winter	40 (32%)

Skin color 2

Very light	2 (2%)

Light	64 (50%)

Intermediate	51 (40%)

Dark	9 (7%)

Exclusive breast feeding 5	90 (71%)

Breastfeeding at week 20	110 (87%)

Infant vitamin D intake, 6 IU/day

Consumers only	96 ± 146

Characteristics (Total n = 126)

Summer	28 (22%)

Autumn	28 (22%)

Winter	40 (32%)

Skin color 2

Very light	2 (2%)

Light	64 (50%)

Intermediate	51 (40%)

Dark	9 (7%)

Exclusive breast feeding 5	90 (71%)

Breastfeeding at week 20	110 (87%)

Infant vitamin D intake, 6 IU/day

Consumers only	96 ± 146


Primer	Sequence (5' - 3')	Product size	Position in coding sequence	Reference

erm(A)-F	CCCGAAAAATACGCAAAATTTCAT	590	15-38	[23]

erm(A)-R	CCCTGTTTACCCATTTATAAACG		604-582

erm(B)-F	TGGTATTCCAAATGCGTAATG	745	203-183

erm(B)-R	CTGTGGTATGGCGGGTAAGT		541-522

mef(A)-F*	CAATATGGGCAGGGCAAG	317	38-55

mef(A)-R*	AAGCTGTTCCAATGCTACGG		352-333

tet(M)-F	GTGGACAAAGGTACAACGAG	406	106-125

tet(M)-R	CGGTAAAGTTCGTCACACAC		511-492

tet(O)- F	AACTTAGGCATTCTGGCTCAC	515	13-43

tet(O)- R	TCCCACTGTTCCATATCGTCA		527-507

tet(K)-F	GATCAATTGTAGCTTTAGGTGAAGG	155	344-368

tet(K)-R	TTTTGTTGATTTACCAGGTACCATT		498-474

tet(L)-F	TGGTGGAATGATAGCCCATT	229	384-403

tet(L)-R	CAGGAATGACAGCACGCTAA		612-593

16S-rDNA-F	GAGTACGACCGCAAGGTTGA	100	886-905

16S-rDNA -R	CTGGTAAGGTTCTTCGCGTTG		985-964

ss-Tn916-1	GCCATGACCTATCTTATA	476	16083-16100	[24]

ss-Tn916-2	CTAGATTGCGTCCAA		16559-16545

tet(32)For	GAACCAGATGCTGCTCTT	620	619-637	[28]

Tet(32)Rev	CATAGCCACGCCCACATGAT		1239-1220

SScps2J-F	CAAACGCAAGGAATTACGGTATC	236	209-231	[29,30]

SScps2J-R	CATTTCCTAAGTCTCGCACC		445-426

tet(L)Ng-F	TCGTTAGCGTGCTGTCATTC	698	680-700	[31]

tet(L)-R-pDG364	CTTAGAAATCCCTTTGAGAAT		1378-1358	This study

tet(W)- F	TTGGAATTCTTGCCCATGTAGACGC	1872	18-42	This study

tet(W)- R	TTGTCCAGGCGGTTGTTTGGAC		1889-1868

tet(W)-F-HN	GGTGCAGTTGGAGGTTGTTT	410	1179-1198

tet(W)-R-HN	CCTTCAATGCCTGTTCCAAT		1569-1588

tet(O)-F-pDG364	ATGAAAATAATTAACTTAGG	1920	1-19

tet(O)-R-pDG364	TTAAGCTAACTTGTGGAACA		1920-1901

ss-tet(M)-whole-F	ACAGACAAAGAACTATCCTTAATG	2500	419-396

ss-tet(M)-whole-R	GTACCCAGTTTAAGAATACCTTTATC		161-136

Additional primers used for sequencing

tet(O)-2-F	TTCAAGACGCCTCCCTGTTC		679-698	This study

tet(O)-2-R	ATTTGGCGGGACTTCTATGTGG		1318-1296

ss-tet(M)-Fseq1	GTTAAATCACTACGATAT		1763-1745

ss-tet(M)-Rseq1	ATAGTGTTCTTGGAGATA		906-929

ss-tet(M)-Fseq2	GTATAATTTCATGTGTCG		1162-1144

ss-tet(M)-Rseq2	AGATGGCGTACAAGCACA		305-323

ss-PAI-P8-tet(M)-R	GCCCTTTTGGGTTTTTGAAT		-33- -14

ss-PAItetM-P9over F	GGGAATCCCCATTTTCCTAA		366-347


	theoretical	measured

	mass content	mass content	molar composition

C	53.0 ± 0.9%	47.3 ± 0.1%	1

H	6.6 ± 0.1%	6.83 ± 0.04%	1.733

O	23.2 ± 0.7%	32.0 ± 0.8%	0.508

	theoretical	measured

	mass content	mass content	molar composition

N	16.7 ± 0.2%	12.7 ± 0.5%	0.23

S	1.6 ± 0.5%	1.00 ± 0.05%	0.008

Total	100.1 ± 2.4%	99.7 ± 0.6%


Initial Experiment Results	Enhanced Results

Total Length Ratio	RMSE (m)	Total Length Ratio	RMSE (m)

0.94	3.2	0.96	0.93


	Acute	Chronic	No Pain	p Value

Total Number (n = 218)	140 (64)	33 (15)	45 (21)

Age n (%)	0.897


Threshold	Net benefit	Point Estimate	Bootstrap Mean	Bootstrap confidence interval

	For:		(2000 replications)	2.5th percentile	97.5th percentile

15	All	0.1288	0.1288	0.0922	0.1669

	Base	0.1288	0.1290	0.0922	0.1669

	Full	0.1590	0.1613	0.1280	0.1955

	Full vs All	0.0302	0.0325	0.0172	0.0490


	AIM HI	CPRT

Initial didactic training—lecture material, video examples, case illustrations, and hands-on practice with coaching and discussion	12 h (over 2 days)	8 h

Ongoing consultation/coaching—occurs while provider delivers intervention to target child and includes video-based feedback1	11 1-h sessions over 6 months (9 group, 2 indiv.)	4 1-h group sessions and 6 individual coaching sessions over 5 months

Total length of training	22 h/6 months	18 h/6 months

	AIM HI	CPRT

Total length of training	22 h/6 months	18 h/6 months


Category	No. of children	No. of diarrheal episodes	Total time at risk (years)	Diarrheal incidence (episodes/child year)	Unadjusted IRR (95% CI)	Adjusted IRR* (95% CI)	P value

Study arm

No intervention	109	85	80.8	1.05 (0.85–1.30)	Ref	Ref	–

Intervention (without safe storage)	65	54	44.1	1.22 (0.94–1.60)	1.15 (0.75–1.77)	1.14 (0.75–1.77)	0.530

Intervention (with safe storage)	102	61	76.8	0.79 (0.62–1.02)	0.77 (0.52–1.14)	0.76 (0.51–1.13)	0.178

Gender

Male	146	102	102.7	0.99 (0.82–1.20)	Ref	Ref	–

Female	130	98	99.0	0.98 (0.81–1.21)	1.00 (0.71–1.40)	1.05 (0.74–1.48)	0.790

Age of child (months)†


Factor

Age

Age ≤40

Age >40

Menopausal status

Premenopausal

Postmenopausal

BMI

BMI <30

BMI ≥30

T stage

Tis, T0–2

T3-4

N stage

N0

N+

Grading

G1-2

G3

Tumor subtype

Luminal A

Others*

Lymphovascular status

LV0

LV1

Type of surgery

Mastectomy

BCS

Residual tumor status

R0

R1


Compound	Description	Applications	Remarks

In111-Capromab pendetide (ProstaScint)	A conjugation between the murine antibody 7E11.C5.3 and 111Inin the source of 111InCl3 by the action of the GYK-DTPA as a chelating agent.	Indicated for use in immunoscintigraphy, proven prostate carcinoma and patients who have undergone a prostatectomy and have rising prostate specific antigen (PSA) values and equivocal nonevidenced metastasis.	It is not indicated with patients with a high clinical suspicion of occult metastatic disease or for screening of prostate carcinoma.

In111-Satumomab pendetide (OncoScint)	It contains the murine MAb B72.3 which is directed to tumor-associated glycoprotein. It is labeled with 111InCl3 by conjugation with the chelating agent, GYK-DTPA.HCl.	Used for the detection of colorectal and ovarian cancers [35].	After an incubation time of 30 min, the labeled mixture is suitable for use in the first 8 hours.

In111-Imciromab pentetate (MyoScint)	An antibody produced against myosin in the cell culture, and therefore binds to the heavy chain of myosin after in vivo administration.	Detection of myocardial infarction.	Contains the Fab fragment of a murine monoclonal antibody that is covalently bound to DTPA giving 111In -Imciromab pentetate.

In-111 and Y90-ibritumomab tiuxetan (Zevalin)	Zevalin consists of a murine monoclonal anti-CD20 antibody covalently conjugated to the metal chelator DTPA, which forms a stable complex with 111Infor imaging and with 90Y for therapy.	90Y-ibritumomab tiuxetan is used for the treatment of some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system while its 111Inderivative is used to scan the predicted distribution of a therapeutic dosage of 90Y-ibritumomab in the body [36].	The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors) allowing radiation from the attached isotope (Yetrium-90) and the cytotoxicity induced by the antibody serve to eliminate B cells from the body allowing a new population of healthy B cells to develop from lymphoid stem cells [37].

Rituximab	An earlier version of anti-CD20 antibody and has also been approved under the brand name Rituxan for the treatment of non-Hodgkin's lymphoma (NHL).	It was approved for the treatment of patients with relapsed or refractory, lowgrade or follicular Bcell NHL, including patients with rituximab refractory follicular NHL.	In September 2009, ibritumomab received approval from the FDA for an expanded label for the treatment of patients with previously untreated follicular NHL, who achieve a partial or complete response to first-line chemotherapy.


Questions	Sub-questions

1. What is the first thing that comes to mind when you hear the phrase “oral health”?	a. aWhat does “good oral health” mean to you?i. bWhen you think of your child, would you say that he or she has “good oral health”?ii. bHow would you describe a child who has good oral health?iii. bThink about your child’s friends, how would you describe those that have good oral health?

2. What comes to mind when you hear the phrase “poor oral health”?	a. aWhen you think of your child, what could be thought of as poor oral health?i. bWhat could be thought as the worst thing for poor oral health?ii. bHow would you describe a child with poor oral health?b. aHow much of a problem is this among children in your family?i. bHow common is it among children in other families who live in this community? Among your friends?ii. bHow concerned are you about your son or daughter developing dental problems (dental decay)?

3. As parents, how do you help your child have healthy teeth?	a. aWhat do you think parents can do (or you as a parent can do) to prevent dental problems in kids (your kids)?b. aAs a parent, what do you think are the most important ways to help a child have good oral health?c. bWhat activities can you do to improve your child’s oral health?d. cWhat about diet and oral health?e. cWhat about flouride and oral health?f. cWhat about the experiences of your other children?

4. Tell me whether you think you can control your child’s oral health?	a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you dealt with an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist?

5. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health?	a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance?

6. What concerns do you have about your child’s future oral health?	a. bAs your child grows older, what oral health problems can affect him/her?i. cHow can poor oral health affect a child’s social and psychological well-being?ii. cHow can it affect a person’s chances of economic success?iii. cHow can it affect one’s general health over a lifetime?

7. Tell me whether you think you can control your child’s oral health?	a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you can dealt an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist?

8. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health?	a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance?

9. What concerns do you have about your child’s future oral health?	a. bAs your child grows older, what oral health problems can affect him/her?

tions	s

1. What is the first thing that comes to mind when you hear the phrase “oral health”?	a. aWhat does “good oral health” mean to you?i. bWhen you think of your child, would you say that he or she has “good oral health”?ii. bHow would you describe a child who has good oral health?iii. bThink about your child’s friends, how would you describe those that have good oral health?

2. What comes to mind when you hear the phrase “poor oral health”?	a. aWhen you think of your child, what could be thought of as poor oral health?i. bWhat could be thought as the worst thing for poor oral health?ii. bHow would you describe a child with poor oral health?b. aHow much of a problem is this among children in your family?i. bHow common is it among children in other families who live in this community? Among your friends?ii. bHow concerned are you about your son or daughter developing dental problems (dental decay)?

3. As parents, how do you help your child have healthy teeth?	a. aWhat do you think parents can do (or you as a parent can do) to prevent dental problems in kids (your kids)?b. aAs a parent, what do you think are the most important ways to help a child have good oral health?c. bWhat activities can you do to improve your child’s oral health?d. cWhat about diet and oral health?e. cWhat about flouride and oral health?f. cWhat about the experiences of your other children?

4. Tell me whether you think you can control your child’s oral health?	a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you dealt with an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist?

5. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health?	a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance?

6. What concerns do you have about your child’s future oral health?	a. bAs your child grows older, what oral health problems can affect him/her?i. cHow can poor oral health affect a child’s social and psychological well-being?ii. cHow can it affect a person’s chances of economic success?iii. cHow can it affect one’s general health over a lifetime?

7. Tell me whether you think you can control your child’s oral health?	a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you can dealt an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist?

8. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health?	a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance?

9. What concerns do you have about your child’s future oral health?	a. bAs your child grows older, what oral health problems can affect him/her?


Dependent variable	Explanatory variable	Beta	Chi‐square	p value	OR (95% confidence interval [CI])

	Female gender	1.13	5.18	.023	3.08 (95% CI [1.17, 8.11])

MMP‐13 saliva

	CAL	1.27	4.35	.037	3.57 (95% CI [1.08, 11.82])

Dependent variable	Explanatory variable	Beta	Chi‐square	p value	OR (95% confidence interval [CI])

MMP‐13 saliva

	CAL	1.27	4.35	.037	3.57 (95% CI [1.08, 11.82])


Patient code	Age (years)	Sex	Clinical form	Location of lesion/Code

 	Cutaneous	Mucosal

1	52	M	MCL	Arm/1MCL-C	Oral / 1MCL-O

2	48	M	MCL	Nostril/2MCL-C	Oral/2MCL-O

3	25	M	MCL	Arm/3MCL-C	Nasal/3MCL-N

4	54	M	MCL	ND	Oral/4MCL-O

5	47	M	MCL	Arm/5MCL-C	Nasal/5MCL-N

Oral/5MCL-O

6	16	M	MCL	ND	Nasal/6MCL-N

7	50	M	MCL	Face/7MCL-C	Nasal/7MCL-N

8	29	M	MCL	Trunk/8LMC-C	Nasal/8MCL-N

9	55	M	MCL	ND	Oral/9MCL-O

10	42	M	MCL	ND	Nasal/10MCL-N

11	52	F	MCL	Arm/11MCL-C	Nasal/11MCL-N

12	25	M	MCL	Trunk/12MCL-C	Oral/12MCL-O

13	52	F	MCL	ND	Oral/13MCL-O

14	54	M	MCL	Upper lip/14MCL-C	Nasal/14MCL-N

15	69	M	MCL	ND	Nasal/15MCL-N

16	65	M	MCL	ND	Oral/16MCL-O

17	63	F	ML	A	Nasal/17ML-N

18	53	M	ML	A	Nasal/18ML-N

19	66	F	ML	A	Nasal/19ML-N

20	71	M	ML	A	Nasal/20ML-N

21	12	M	ML	A	Nasal/21ML-N

22*	49	F	ML	A	Nasal/22ML-N

23*	69	M	ML	A	Nasal/23ML-N

24*	60	M	ML	A	Nasal/24ML-N

25*	77	M	ML	A	Nasal/25ML-N

26*	72	M	ML	A	Nasal/26ML-N

27*	71	F	ML	A	Nasal/27ML-N

28*	39	M	ML	A	Nasal/28ML-N

29*	63	M	ML	A	Nasal/29ML-N

30*	44	F	ML	A	Nasal/30ML-N

31*	31	F	ML	A	Nasal/31ML-N1

Nasal/31ML-N2

32*	29	F	ML	A	Nasal/32ML-N1

Nasal/32ML-N2

33*	72	F	ML	A	Oral/33LM-O

34	49	M	DL	Arm/ 34DL-C1	Nasal/34DL-N

Trunk/34DL-C2

Leg/34DL-C3

35	41	M	DL	Nose/35DL-C	Nasal/35DL-N

 	 	 	 	 	Oral/35DL-O

Patient code	Age (years)	Sex	Clinical form	Location of lesion/Code

	Cutaneous	Mucosal

18	53	M	ML	A	Nasal/18ML-N

19	66	F	ML	A	Nasal/19ML-N

20	71	M	ML	A	Nasal/20ML-N

21	12	M	ML	A	Nasal/21ML-N

22*	49	F	ML	A	Nasal/22ML-N

23*	69	M	ML	A	Nasal/23ML-N

24*	60	M	ML	A	Nasal/24ML-N

25*	77	M	ML	A	Nasal/25ML-N

26*	72	M	ML	A	Nasal/26ML-N

27*	71	F	ML	A	Nasal/27ML-N

28*	39	M	ML	A	Nasal/28ML-N

29*	63	M	ML	A	Nasal/29ML-N

30*	44	F	ML	A	Nasal/30ML-N

31*	31	F	ML	A	Nasal/31ML-N1

Nasal/31ML-N2

32*	29	F	ML	A	Nasal/32ML-N1

Nasal/32ML-N2

33*	72	F	ML	A	Oral/33LM-O

34	49	M	DL	Arm/ 34DL-C1	Nasal/34DL-N

Trunk/34DL-C2

Leg/34DL-C3

35	41	M	DL	Nose/35DL-C	Nasal/35DL-N

					Oral/35DL-O


Diagnosis	n	Percent

Small for gestational age	11	26.8

Disseminated intravascular coagulation	5	12.2

Respiratory distress syndrome	7	17.1

Sepsis	21	51.2

Anemia	2	4.9

Shock	5	12.2

Meconium aspiration syndrome	2	4.9

Hypoxic ischaemic encephalopathy	19	46.3

Acute kidney injury	7	17.1

Meningitis	2	4.9

Pulmonary hemorrhage	2	4.9

Hyperbilirubinemia	3	7.3

Necrotising enterocolitis	1	2.4

Persistent pulmonary hypertension	3	7.3

Intracranial haemorrhage	1	2.4

Congenital heart disease	6	14.6


Gastric ulcer model	Treatments (p.o.)	Dose (g/kg)	n	Ulcer index (mm)	Inhibition (%)

Ethanol-induced	Saline	–	8	14.37 ± 2.88	–

Ranitidine	0.04	8	11.27 ± 2.49∗∗	29.01

AIG	1.50	8	3.11 ± 0.47∗∗	80.43

AIG	0.75	8	4.46 ± 0.51∗∗	71.93

Pylorus ligature-induced	Saline	–	8	11.33 ± 3.78	–

Ranitidine	0.03	8	3.55 ± 0.63∗∗	68.68

AIG	1.0	8	2.76 ± 0.67∗∗	75.63

AIG	0.5	8	3.36 ± 0.78∗∗	70.33

Acetic acid-induced	Saline	–	8	10.26 ± 1.52	–

Ranitidine	0.03	8	3.89 ± 0.48∗∗	64.37

AIG	1.0	8	2.84 ± 0.53∗∗	72.49

AIG	0.5	8	3.38 ± 0.64∗∗	63.15

Gastric ulcer model	Treatments (p.o.)	Dose (g/kg)	n	Ulcer index (mm)

Ethanol-induced	Saline	–	8	14.37 ± 2.88

Ranitidine	0.04	8	11.27 ± 2.49∗∗

AIG	1.50	8	3.11 ± 0.47∗∗

AIG	0.75	8	4.46 ± 0.51∗∗

Pylorus ligature-induced	Saline	–	8	11.33 ± 3.78

Ranitidine	0.03	8	3.55 ± 0.63∗∗

AIG	1.0	8	2.76 ± 0.67∗∗

AIG	0.5	8	3.36 ± 0.78∗∗

Acetic acid-induced	Saline	–	8	10.26 ± 1.52

Ranitidine	0.03	8	3.89 ± 0.48∗∗

AIG	1.0	8	2.84 ± 0.53∗∗

AIG	0.5	8	3.38 ± 0.64∗∗


Most significant GO Biological Processes

GO Term	GO ID	Changed Genes	Total Genes in Class	P-Value	Fraction

Cholesterol biosynthesis	GO:0006695	12	20	7.04E-09	0.600

Nuclear mRNA splicing, via spliceosome	GO:0000398	29	110	9.77E-09	0.264

glycolysis	GO:0006096	14	39	1.16E-07	0.359

Protein biosynthesis	GO:0006412	38	247	8.00E-07	0.154

transport	GO:0006810	50	415	8.94E-07	0.120

Protein metabolism	GO:0019538	9	17	4.90E-06	0.529

Protein folding	GO:0006457	28	174	5.59E-06	0.161

Ribosome biogenesis	GO:0007046	6	14	3.22E-05	0.429

metabolism	GO:0008152	39	316	9.36E-05	0.123

tRNA processing	GO:0008033	8	33	5.32E-04	0.242

Regulation of the cyclin dependent protein kinase activity	GO:0000079	8	34	9.72E-04	0.235

Amino acid biosynthesis	GO:0008652	6	22	1.01E-03	0.273

Lipid metabolism	GO:0006629	24	193	1.02E-03	0.124

Regulation of progression through cell cycle	GO:0000074	27	200	1.14E-03	0.135

Cell cycle	GO:0007049	41	338	1.64E-03	0.121

Regulation of translational initiation	GO:0006446	7	22	1.88E-03	0.318

Most significant GO Molecular Function.

GO Term	GO ID	Changed Genes	Total Genes in Class	P-Value	Fraction

Nucleotide binding	GO:0000166	173	1405	6.92E-11	0.123

RNA binding	GO:0003723	78	389	4.22E-10	0.201

Oxidoreductase activity	GO:0016491	61	382	6.44E-10	0.160

ATP binding	GO:0005524	123	1116	1.20E-09	0.110

Unfolded protein binding	GO:0051082	28	143	2.68E-08	0.196

Protein binding	GO:0005515	220	2514	1.77E-07	0.088

Transferase activity	GO:0016740	101	958	1.86E-07	0.105

L-ascorbic acid binding	GO:0031418	6	11	1.65E-05	0.545

Lyase activity	GO:0016829	16	89	1.37E-04	0.180

binding	GO:0005488	47	399	2.37E-04	0.118

ATP-dependent RNA helicase activity	GO:0004004	7	18	4.61E-04	0.389

Isomerase activity	GO:0016853	15	90	5.54E-04	0.167

Ligase activity	GO:0016874	27	184	5.54E-04	0.147

Oxidoreductase activity	GO:0016702	6	18	6.72E-04	0.333

NAD binding	GO:0051287	8	24	7.05E-04	0.333

Catalytic activity	GO:0003824	27	192	7.40E-04	0.141

Transporter activity	GO:0005215	29	281	1.50E-03	0.103

Kinase activity	GO:0016301	22	163	1.65E-03	0.135

tRNA binding	GO:0000049	5	13	1.87E-03	0.385

Most significant GO Cellular Component

GO Term	GO ID	Changed genes	Total genes in class	P-value	Fraction

cytoplasm	GO:0005737	114	895	5.00E-10	0.127

nucleus	GO:0005634	281	2999	5.00E-10	0.094

mitochondrion	GO:0005739	70	528	1.01E-09	0.133

endoplasmic reticulum	GO:0005783	49	405	2.47E-06	0.121

mitochondrial inner membrane presequence translocase complex	GO:0005744	5	11	2.82E-04	0.455

soluble fraction	GO:0005625	24	194	3.22E-04	0.124

nucleolus	GO:0005730	12	59	1.09E-03	0.203

Most significant GO Biological Processes

GO Term	GO ID	Changed Genes	Total Genes in Class	P-Value	Fraction

Cholesterol biosynthesis	GO:0006695	12	20	7.04E-09	0.600

Nuclear mRNA splicing, via spliceosome	GO:0000398	29	110	9.77E-09	0.264

glycolysis	GO:0006096	14	39	1.16E-07	0.359

Protein biosynthesis	GO:0006412	38	247	8.00E-07	0.154

transport	GO:0006810	50	415	8.94E-07	0.120

Protein metabolism	GO:0019538	9	17	4.90E-06	0.529

Protein folding	GO:0006457	28	174	5.59E-06	0.161

Ribosome biogenesis	GO:0007046	6	14	3.22E-05	0.429

metabolism	GO:0008152	39	316	9.36E-05	0.123

tRNA processing	GO:0008033	8	33	5.32E-04	0.242

Regulation of the cyclin dependent protein kinase activity	GO:0000079	8	34	9.72E-04	0.235

Amino acid biosynthesis	GO:0008652	6	22	1.01E-03	0.273

Lipid metabolism	GO:0006629	24	193	1.02E-03	0.124

Regulation of progression through cell cycle	GO:0000074	27	200	1.14E-03	0.135

Cell cycle	GO:0007049	41	338	1.64E-03	0.121

Regulation of translational initiation	GO:0006446	7	22	1.88E-03	0.318

Most significant GO Molecular Function.

GO Term	GO ID	Changed Genes	Total Genes in Class	P-Value	Fraction

Nucleotide binding	GO:0000166	173	1405	6.92E-11	0.123

RNA binding	GO:0003723	78	389	4.22E-10	0.201

Oxidoreductase activity	GO:0016491	61	382	6.44E-10	0.160

ATP binding	GO:0005524	123	1116	1.20E-09	0.110

Unfolded protein binding	GO:0051082	28	143	2.68E-08	0.196

Protein binding	GO:0005515	220	2514	1.77E-07	0.088

Transferase activity	GO:0016740	101	958	1.86E-07	0.105

L-ascorbic acid binding	GO:0031418	6	11	1.65E-05	0.545

Lyase activity	GO:0016829	16	89	1.37E-04	0.180

binding	GO:0005488	47	399	2.37E-04	0.118

ATP-dependent RNA helicase activity	GO:0004004	7	18	4.61E-04	0.389

I		15	90		0.16

Most significant GO Biological Processes

somerase activity	GO:0016853			5.54E-04	7

Ligase activity	GO:0016874	27	184	5.54E-04	0.147

Oxidoreductase activity	GO:0016702	6	18	6.72E-04	0.333

NAD binding	GO:0051287	8	24	7.05E-04	0.333

Catalytic activity	GO:0003824	27	192	7.40E-04	0.141

Transporter activity	GO:0005215	29	281	1.50E-03	0.103

Kinase activity	GO:0016301	22	163	1.65E-03	0.135

tRNA binding	GO:0000049	5	13	1.87E-03	0.385

Most significant GO Cellular Component

GO Term	GO ID	Changed genes	Total genes in class	P-value	Fraction

cytoplasm	GO:0005737	114	895	5.00E-10	0.127

nucleus	GO:0005634	281	2999	5.00E-10	0.094

mitochondrion	GO:0005739	70	528	1.01E-09	0.133

endoplasmic reticulum	GO:0005783	49	405	2.47E-06	0.121

mitochondrial inner membrane presequence translocase complex	GO:0005744	5	11	2.82E-04	0.455

soluble fraction	GO:0005625	24	194	3.22E-04	0.124

nucleolus	GO:0005730	12	59	1.09E-03	0.203


Parameters	Vildagliptin (n-29)	P value*	Placebo (n-29)	P value*	P value+

	Pre treatment	Post treatment		Pre-treatment	Post treatment


Feature	Control group (A)	Study group (B)

Number of pin-sites	268	368

AO tubular external fixation	43	41

Unilateral rail	0	2

Ilizarov device	6	8

Pin tract infection (patients)a	11 (22.5 %)	2 (4.1 %)

Pin tract infection (pin-sites)a	38 (14.2 %)	7 (1.9 %)

Feature

Number of pin-sites

AO tubular external fixation

Unilateral rail

Ilizarov device

Pin tract infection (patients)a

Pin tract infection (pin-sites)a


Trials	 	Intervention (n/N)	Control (n/N)	RR (95% CI)	P value

LWDHW plus enalapril versus enalapril	1	34/42	21/36	3.04 (1.10, 8.38)	0.03

Meta-analysis	1	34/42	21/36	3.04 (1.10, 8.38)	0.03


	Non-hospitalsN = 191	HospitalsN = 34	Chi-square (p-value)

	Yesn (%)	Don't normally stockn (%)	Yesn (%)	Don't normally stockn (%)

AMT	17	18	2	13	23.0 (.0001)

CQ	111	1	5	1	20.4 (.0001)


Isolate	Collection	Country	Yr of entry into collection	Sequencing technology	Reference

NCTC86_Dunne	NCTC	England	1920	Pacific Biosciences RS II, Illumina	2

NCTC86_Meric	NCTC	England	1920	Illumina MiSeq	4

NCTC86	NCTC	England	1920	Illumina MiSeq	This study

CIP61.11	Centre de Ressources Biologiques de l’Institut Pasteur	France	1961	Illumina MiSeq	This study

ATCC 4157	ATCC	United States	Unknown	Illumina MiSeq	This study

DSM301	DSMZ	Germany	1970	Illumina MiSeq	This study

Isolate	Collection	Country	Yr of entry into collection	Sequencing technology

NCTC86_Dunne	NCTC	England	1920	Pacific Biosciences RS II, Illumina

NCTC86_Meric	NCTC	England	1920	Illumina MiSeq

NCTC86	NCTC	England	1920	Illumina MiSeq

CIP61.11	Centre de Ressources Biologiques de l’Institut Pasteur	France	1961	Illumina MiSeq

ATCC 4157	ATCC	United States	Unknown	Illumina MiSeq

DSM301	DSMZ	Germany	1970	Illumina MiSeq

Reference

2

4

This study

This study

This study

This study


	Placebo (N = 112)	25 mg/d Neramexane (N = 108)	50 mg/d Neramexane (N = 107)	75 mg/d Neramexane (N = 102)

	n	%	n	%	n	%	n	%


Prevalence of elevated CRP (>10 mg/L)

Group		%	Univariate p-value	Multivariate OR *	Multivariate p-value**

Age	<50	14	0.49

	50–59	13

	60–69	13

	70+	18

Sex	Male	14	0.28

	Female	18

NIHSS	<7	13	0.015	(ref)	0.03

	7–13	25		2.15

	14+	21		1.89

OCSP classification	LACI	15	0.005

	TACI	26

	PACI	10

	POCI	19

Prior Cerebrovascular disease	No	16	0.97

	Yes	16

Pre-existing diabetes mellitus	No	14	0.01	(ref)	0.04

	Yes	27		1.96

Smoking habits	Never smoker	19	0.29

	Former smoker	14

	Current smoker	12

Time to hospital	<3 hours	13	0.20

	3–5.9 hours	20

	6–11.9 hours	10

	12–23.9 hours	18

	Woke up with Stroke (<24 hours)	17

	Other (<24 hours)	26

Prevalence of elevated CRP (>10 mg/L)

Group		%	Univariate p-value

Age	<50	14	0.49

	50–59	13

	60–69	13

	70+	18

Sex	Male	14	0.28

	Female	18

NIHSS	<7	13	0.015

	7–13	25

	14+	21

OCSP classification	LACI	15	0.005

	TACI	26

	PACI	10

	POCI	19

Prior Cerebrovascular disease	No	16	0.97

	Yes	16

Pre-existing diabetes mellitus	No	14	0.01

	Yes	27

Smoking habits	Never smoker	19	0.29

	Former smoker	14

	Current smoker	12

Time to hospital	<3 hours	13	0.20

	3–5.9 hours	20

	6–11.9 hours	10

	12–23.9 hours	18

	Woke up with Stroke (<24 hours)	17

	Other (<24 hours)	26

Prevalence of elevated CRP (>10 mg/L)

Multivariate OR *	Multivariate p-value**

(ref)	0.03

2.15

1.89

(ref)	0.04

1.96


	Insular cortex	Posterior cingulate cortex

	Right	Left

No. of participants	4	4	4

Peak latency (ms)	191.0 ± 10.6	184.0 ± 4.6	468.0 ± 13.5


	Males (n = 196)	Females (n = 210)	Total (n = 406)

Career aspiration	Mean (SD)	Mean (SD)	Mean (SD)

Effect	F	P	Partial eta squared

Gender	F(1,400) = 21.77	0.001	0.05

Career aspiration	F(2,400) = 101.61	<0.001	0.34

Gender × Career aspiration	F(2,400) = 2.04	0.131	0.01


	Odds ratio	95% Confidentialinterval	P-value

Laboratory variables

Gamma-glutamyltranspeptidase, IU/L	1.009	0.953, 1.068	0.757

Cumulative dose of medications, mg

Leflunomide (53 patients)	1.000	1.000, 1.000	0.007

Prednisolone (89 patients)	1.000	1.000, 1.000	0.547

	Odds ratio	95% Confidentialinterval	P-value

Cumulative dose of medications, mg

Leflunomide (53 patients)	1.000	1.000, 1.000	0.007

Prednisolone (89 patients)	1.000	1.000, 1.000	0.547


Clinical presentatiton	No. of patients	No. of episods	Time* (median/month)	Treatment

Cholangitis	5	9	19.5 (14–47)	Medical

 -without real stricture	3	3	28.3	Medical

 -with real stricture	2	6	15.5	Endoscopic (dilatation and/or stenting)

CBD stone	2	2	21.5 (16–27)	Endoscopic (stone extraction)

Total	7	11

Clinical present	No. of patien	No. of episods	Time* (median/month	Treatme

atiton	ts		)	nt

Cholangitis	5	9	19.5 (14–47)	Medical

-without real stricture	3	3	28.3	Medical

-with real stricture	2	6	15.5	Endoscopic (dilatation and/or stenting)

CBD stone	2	2	21.5 (16–27)	Endoscopic (stone extraction)

Total	7	11


	Awareness of ESCCAP Heartworm Guidelines

	Number clinics responding (% responding)

Country	Not aware	Slightly aware	Moderately aware	Quite aware	Very aware	Responders

UK (non-endemic)	22 (67)	5 (15)	3 (9)	3 (9)	0 (0)	33

Germany (non-endemic)	40 (40)	38 (38)	20 (20)	3 (3)	0 (0)	101

Netherlands (non-endemic)	32 (94)	1 (3)	1 (3)	0 (0)	0 (0)	34

France (non-endemic)	63 (73)	9 (10)	10 (12)	2 (2)	2 (2)	86

France (endemic)	29 (62)	9 (19)	4 (9)	4 (9)	1 (2)	47

Spain (non-endemic)	25 (37)	13 (19)	22 (32)	6 (9)	2 (3)	68

	Awareness of ESCCAP Heartworm Guidelines

	Number clinics responding (% responding)

Country	Not aware	Slightly aware	Moderately aware	Quite aware	Very aware	Responders

Spain (endemic)	15 (37)	4 (10)	10 (24)	9 (22)	3 (7)	41

Italy (non-endemic)	35 (52)	11 (16)	14 (21)	5 (7)	2 (3)	67

Italy (endemic)	56 (52)	19 (18)	20 (19)	8 (7)	4 (4)	107

Total (non-endemic)	217 (56)	77 (20)	70 (18)	19 (5)	6 (2)	389

Total (endemic)	100 (51)	32 (16)	34 (17)	21 (11)	8 (4)	195

Total	317 (54)	109 (19)	104 (18)	40 (7)	14 (2)	584


Type of model or algorithm	Target product	Model-based target: knockout gene A or overexpress gene B	References

Dynamic flux balance analysis	Ethanol	Ethanol production pathway after 20 h	[163]

Genome-scale metabolic model	Prediction of growth rate with respect to photosynthetic quotient for ethanol and butanol production	Double reaction knock out of hydrolyase and dehydrogenase	[164]

In vivo carbon flux analysis	Homolanthionine	Deletion of methionine and cysteine biosynthesis repressor protein	[165]

Metabolic flux analysis	Hydrogen production	Deletion and addition of GAP1 and dehydrogenase, respectively	[166]

Metabolic flux analysis	Astaxanthin synthesis	–	[167]

Metabolic flux analysis	Fixed more CO2 and had a higher biomass yield	Alternate pathway for isoleucine synthesis (via citramalate synthase, CimA	[168]

Metabolic net fluxes	Hydrogen production	Disruption of hydrogenase and poly-β-hydroxybutyrate synthase	[169]

Type of model or algorithm	Target product	Model-based target: knockout gene A or overexpress gene B	References

Metabolic flux analysis	Astaxanthin synthesis	–	[167]

Metabolic flux analysis	Fixed more CO2 and had a higher biomass yield	Alternate pathway for isoleucine synthesis (via citramalate synthase, CimA	[168]

Metabolic net fluxes	Hydrogen production	Disruption of hydrogenase and poly-β-hydroxybutyrate synthase	[169]


Severity of stress

n = 85	%

Severe	33

Moderate	27

Extreme	22

None/light	8

Catastrophic	6

Severity of stress

n = 85

Severe

Moderate

Extreme

None/light

Catastrophic


	Any first-degree relative

	History of cancer (any site)	History of head and neck cancer

	‡No	Yes	OR (95% CI)†	§No	Yes	OR (95% CI)†

	Cases/controls	Cases/controls		Cases/controls	Cases/controls

Smoking

Never	19/563	27/559	1.1 (0.6-2.1)	35/994	6/51	2.4 (1.0-7.0)

Ever	231/1002	306/1030	1.3 (1.1-1.5)	427/1785	58/104	2.7 (1.8-3.4)

Drinking


	Pre-VT SC-IAT	Embodiment after first session of VT	Embodiment after second session of VT	Post-VT SC-IAT

	M	SD	M	SD	M	SD	M	SD

Synch black	0.01	0.38	0.91	1.32	1.14	1.31	0.05	0.30

	Pre-VT SC-IAT	Embodiment after first session of VT	Embodiment after second session of VT	Post-VT SC-IAT

	M	SD	M	SD	M	SD	M	SD

Synch white	-0.05	0.35	1.32	1.46	1.31	1.68	-0.01	0.37

Asynch black	0.01	0.44	-0.82	1.51	-0.39	1.71	-0.11	0.28

Asynch white	0.05	0.35	-0.93	1.46	-0.74	1.64	0.10	0.37


Group	n	Age (year)	Infertility duration (year)	BMI	Reproductive hormone level

FSH/IU·L-1	LH/IU·L-1	E2/pg·mL-1	T/mmol·L-1

LE group	52	26.4±4.2	3.4±1.1	22.4±4.5	7.1±1.5	5.7±1.1	57.7±13.5	1.41±0.5

CC		27.1±4.	3.	23.4	6.9±1.	5.	54.5±12	1.45


	Input type	Database update	Functional Database support	Multiple organism support	Limitations for input genes	Statistics

GeneSCF v1.1	List of genes	Real-time	KEGG, GO, Reactome and NCG	Yes	No upper or lower limit	FE test a & FDR b

GeneSCF v1.0	List of genes	Manual (preparation needed)	KEGG, GO, Reactome and NCG	No (Homo sapiens)	No upper or lower limit	FE test & FDR

GOrilla	List of genes	Weekly auto-update	GO	Yes	No upper limit but has lower limit	FE test & FDR

DAVID 6.7	List of genes	Last known update 2010)	KEGG, GO, Reactome and Biocarta	Yes	Upper limit 3000 and no lower limit	FE test & FDR

	Input type	Database update	Functional Database support	Multiple organism support	Limitations for input genes	Statistics

GeneSCF v	List of g	R	KEGG, GO, Reactome a		No upper or lower	FE

1.1	enes	eal-time	nd NCG	Yes	 limit	test a & FDR b

GeneSCF v1.0	List of genes	Manual (preparation needed)	KEGG, GO, Reactome and NCG	No (Homo sapiens)	No upper or lower limit	FE test & FDR

GOrilla	List of genes	Weekly auto-update	GO	Yes	No upper limit but has lower limit	FE test & FDR

DAVID 6.7	List of genes	Last known update 2010)	KEGG, GO, Reactome and Biocarta	Yes	Upper limit 3000 and no lower limit	FE test & FDR


DHFR	Regions (%)	Total N (%)

Repeat Type	Delhi	Nadiad	Panna	Chennai	Kamrup

Total (N)	20	20	18*	20	19*	97


Items	Cronbach’s alpha if items were deleted

Physical functioning	0.845

Mental health	0.847

Vitality	0.849

Role physical	0.858

General health	0.853

Bodily pain	0.857

Role emotional	0.862

Social functioning	0.856

Educational rescue policy	0.871

Orphan rescue policy	0.871

Employment rescue policy	0.871

Poverty rescue policy	0.871

Social security policy	0.872

Legal rescue policy	0.872

Items

Physical functioning

Mental health

Vitality

Role physical

General health

Bodily pain

Role emotional

Social functioning

Educational rescue policy

Orphan rescue policy

Employment rescue policy

Poverty rescue policy

Social security policy

Legal rescue policy


Crude extracta	Yieldb(g)	Yieldc(% of pollen sample)	Appearance

Corn bee pollen extracts

CMEb	35.29	8.40	Dark brown sticky solid

CDEb	2.40	0.57	Dark brown solid

CHEb	18.13	4.32	Yellow solid

Floral corn pollen extracts

CMEp	9.02	2.15	Dark brown solid

CDEp	4.82	1.15	Brown solid

CHEp	7.87	1.87	Dark green oil/wax

Crude extracta	Yieldb(g)	Yieldc(% of pollen sample)	Appearance

CMEp	9.02	2.15	Dark brown solid

CDEp	4.82	1.15	Brown solid

CHEp	7.87	1.87	Dark green oil/wax


The Job stress Survey (JSS) Items	Lack of support leaders	Demanding job tasks	Time pressure	Lack of support co-workers

No participating in decisions	0.84	0.20	0.03	0.04

Lack recognition for good work	0.80	0.14	0.03	0.28

Poor or inadequate supervision	0.61	0.28	0.13	0.18

Difficult working with superior	0.81	0.16	0.17	0.19

Inadequate support by supervisor	0.57	0.24	0.19	0.25

Difficulty getting along with supervisor	0.79	0.01	0.19	0.22

Working overtime	0.16	0.56	0.05	0.12

Critical on the spot decisions	0.20	0.73	0.16	0.10

Assigned increased responsibility	0.32	0.62	0.19	0.11

Assignment of new duties	0.11	0.75	0.24	0.03

Perform duties not in job description	0.04	0.67	0.33	0.16

Frequent interruptions	0.26	0.28	0.53	0.42

Frequent change simple to demanding tasks	0.06	0.44	0.61	0.16

Excessive paperwork	0.09	0.19	0.79	0.12

Meeting deadline	0.06	0.20	0.82	0.14

Insufficient personal time	0.24	0.12	0.66	0.04

Fellow workers not doing job	0.26	0.21	0.01	0.77

Covering work for others	0.31	0.18	0.27	0.56

Poorly motivated co-workers	0.26	0.05	0.24	0.79

Sums of squared loadings	3.9	2.9	2.9	2.1

% variance	20.4	15.3	15.1	11.0

The Norwegian Ambulance Stress Survey (NASS)	Non-Emergency tasks	Serious operational tasks	Physical demands

Hide feelings towards patients and relatives		0.83	0.13	0.16

Not being able to express own opinion to patients or relatives		0.82	0.08	0.19

Medical responsibility in the vehicle		0.63	0.34	0.17

Negative attitude from relatives about the job you are doing		0.60	0.29	0.07

The cumulative effect of frequently driving chronically ill patients		0.54	0.25	0.24

Take care of seriously injured and dying patients		0.52	0.57	0.15

Uncertainty about what you will meet on the scene of accident		0.51	0.60	0.11

Incident with seriously injured friend or people you know		0.19	0.73	0.12

Incident with seriously injured children		0.09	0.83	0.15

Deal with acting-out and threatening patients		0.18	0.70	0.22

Driving under difficult conditions		0.34	0.62	0.18

Heavy lifting		0.22	0.12	0.91

Carrying out the work under difficult conditions		0.20	0.22	0.91

Working in bent or twisted positions		0.18	0.25	0.87

Sums of squared loadings		3.3	3.2	2.7

% variance		23.3	22.7	19.3

The Job stress Survey (JSS) Items	Lack of support leaders	Demanding job tasks	Time pressure	Lack of support co-workers

No participating in decisions	0.84	0.20	0.03	0.04

Lack recognition for good work	0.80	0.14	0.03	0.28

Poor or inadequate supervision	0.61	0.28	0.13	0.18

Difficult working with superior	0.81	0.16	0.17	0.19

Inadequate support by supervisor	0.57	0.24	0.19	0.25

Difficulty getting along with supervisor	0.79	0.01	0.19	0.22

Working overtime	0.16	0.56	0.05	0.12

Critical on the spot decisions	0.20	0.73	0.16	0.10

Assigned increased responsibility	0.32	0.62	0.19	0.11

Assignment of new duties	0.11	0.75	0.24	0.03

Perform duties not in job description	0.04	0.67	0.33	0.16

Frequent interruptions	0.26	0.28	0.53	0.42

Frequent change simple to demanding tasks	0.06	0.44	0.61	0.16

Excessive paperwork	0.09	0.19	0.79	0.12

Meeting deadline	0.06	0.20	0.82	0.14

Insufficient personal time	0.24	0.12	0.66	0.04

Fellow workers not doing job	0.26	0.21	0.01	0.77

Covering work for others	0.31	0.18	0.27	0.56

Poorly motivated co-workers	0.26	0.05	0.24	0.79

Sums of squared loadings	3.9	2.9	2.9	2.1

% va	20.	15.3	15.1	11.

riance	4			0

The Norwegian Ambulance Stress Survey (NASS)	Non-Emergency tasks	Serious operational tasks	Physical demands

Hide feelings towards patients and relatives		0.83	0.13	0.16

Not being able to express own opinion to patients or relatives		0.82	0.08	0.19

Medical responsibility in the vehicle		0.63	0.34	0.17

Negative attitude from relatives about the job you are doing		0.60	0.29	0.07

The cumulative effect of frequently driving chronically ill patients		0.54	0.25	0.24

Take care of seriously injured and dying patients		0.52	0.57	0.15

Uncertainty about what you will meet on the scene of accident		0.51	0.60	0.11

Incident with seriously injured friend or people you know		0.19	0.73	0.12

Incident with seriously injured children		0.09	0.83	0.15

Deal with acting-out and threatening patients		0.18	0.70	0.22

Driving under difficult conditions		0.34	0.62	0.18

Heavy lifting		0.22	0.12	0.91

Carrying out the work under difficult conditions		0.20	0.22	0.91

Working in bent or twisted positions		0.18	0.25	0.87

Sums of squared loadings		3.3	3.2	2.7

% variance		23.3	22.7	19.3


Cut-off	No of studies	Co-sensitivity (95 % CI)	Co-specificity (95 % CI)	I2 (95%CI)	Pooled positive LR	Pooled negative LR

1.5 cm	1	0.93	0.16	–	1.1	0.43

	2	0.	0.41		1.61, 1	0.12,


 	Men	Women	p-value*

Number of patients	289	284

Number of deaths	41	21

Number of admissions	1924	3139

Total time of follow-up (person-years)	3420	3204

Follow-up time in years (mean, SD)	11.8 (7.4)	11.3 (7.4)	0.37

Age at first admission in years (mean, SD)	31.2 (9.9)	30.2(12.2)	0.28

Total number of days admitted (median, 1 and 3 quartile)	70 (18.0, 214.5)	111 (25.3, 293.0)	0.013

Number of admissions (median, 1 and 3 quartile)	3 (1,8)	4 (2,1)	0.004

% with personality disorder as only diagnosis (N)	30.1 (89)	23.9 (68)	0.07

	Men	Women	e*

Number of patients	289	284

Number of deaths	41	21

Number of admissions	1924	3139

Total time of follow-up (person-years)	3420	3204

Follow-up time in years (mean, SD)	11.8 (7.4)	11.3 (7.4)	0.37

Age at first admission in years (mean, SD)	31.2 (9.9)	30.2(12.2)	0.28

Total number of days admitted (median, 1 and 3 quartile)	70 (18.0, 214.5)	111 (25.3, 293.0)	0.013

Number of admissions (median, 1 and 3 quartile)	3 (1,8)	4 (2,1)	0.004

% with personality disorder as only diagnosis (N)	30.1 (89)	23.9 (68)	0.07


PBMS	DMT status

Domains	pre-test	RCT	pos-	p-value

 	Sub-domains	without /with	without /with	sible range	pre	RCT

1: Attitude	2.1 / 4.6	2.4 / 4.1	0-9	<.01	<.01

 	a: expectations regarding outcomes	1.4 / 2.0	1.5 / 1.9	0-3	<.01	<.01

 	b: values of expected outcomes	1.4 / 2.2	1.5 / 2.1	0-3	<.01	<.01

2: Social norm	1.2 / 1.8	1.5 / 2.4	0-9	.23	<.01

 	a: assumed attitudes of important others	1.2 / 2.0	1.5 / 2.2	0-3	<.01	<.01

 	b: motivation to comply with these norms	1.0 / .9	1.0 / 1.1	0-3	<.01	.34

3: Control beliefs	1.6 / 4.7	2.1 / 4.1	0-9	<.01	<.01

 	a: assumed facilitators or barriers	1.0 / 2.1	1.2 / 1.9	0-3	<.01	<.01

 	b: perceived power of these factors	1.4 / 2.2	1.5 / 2.0	0-3	<.01	<.01

Intention estimate	4.8 / 11.1	6.0 / 10.1	0-27	<.01	<.01

PBMS	DMT status

Domains	pre-test	RCT	pos-	p-value

			without /w		pr	RCT

	Sub-domains	without /with	ith	sible range	e

1: Attitude	2.1 / 4.6	2.4 / 4.1	0-9	<.01	<.01

	a: expectations regarding outcomes	1.4 / 2.0	1.5 / 1.9	0-3	<.01	<.01

	b: values of expected outcomes	1.4 / 2.2	1.5 / 2.1	0-3	<.01	<.01

2: Social norm	1.2 / 1.8	1.5 / 2.4	0-9	.23	<.01

	a: assumed attitudes of important others	1.2 / 2.0	1.5 / 2.2	0-3	<.01	<.01

	b: motivation to comply with these norms	1.0 / .9	1.0 / 1.1	0-3	<.01	.34

3: Control beliefs	1.6 / 4.7	2.1 / 4.1	0-9	<.01	<.01

	a: assumed facilitators or barriers	1.0 / 2.1	1.2 / 1.9	0-3	<.01	<.01

	b: perceived power of these factors	1.4 / 2.2	1.5 / 2.0	0-3	<.01	<.01

Intention estimate	4.8 / 11.1	6.0 / 10.1	0-27	<.01	<.01


SNP	Position	Alleles†	MAF	Beta	s.e.	P	Pemp


Characteristics	Yes (%)	No (%)

Ever received an introduction into work place ergonomics	24 (14.7%)	136 (83.4%)

Ever experienced work-related musculoskeletal problems	123 (75.5%)	40 (24.5%)

Musculoskeletal problems in the last four weeks (n=123)	69 (56.1%)	53 (43.1%)

Signed off due musculoskeletal problems last year (n=123)	11 (8.9%)	112 (91.1%)

Doing regularly short breaks for stretching exercises	36 (22.1%)	124 (76.1%)

Any known ametropia	145 (89.0%)	17 (10.4%)

Aggravation of ametropia since working in pathology (n=145)	82 (56.6%)	58 (40.0%)

Eye fatigue symptoms in the last month	90 (55.2%)	68 (41.7%)

Ever experienced occupational injuries in pathology	135 (82.8%)	28 (17.2%)

Experienced such injuries in the last year (n=135)	37 (27.4%)	95 (70.4%)

Remaining permanent damages from such injuries (n=135)	5 (3.7%)	127 (94.1%)

Ever experienced intolerance reactions against formalin	41 (25.2%)	118 (72.4%)

Any known allergy	55 (33.7%)	105 (64.4%)

Since working in pathology ever diseased with...

Tuberculosis	2 (1.2%)	153 (93.9%)

Positive tuberculin test only	31 (19.0%)	119 (73.0%)

Hepatitis B	1 (0.6%)	154 (94.5%)

Hepatitis C	0 (0.0%)	155 (95.1%)

HIV	0 (0.0%)	154 (94.5%)

Burnout	14 (8.6%)	141 (86.5%)

Depression	11 (6.7%)	144 (88.3%)

Hypertension	11 (6.7%)	144 (88.3%)

Diabetes mellitus type II	3 (1.8%)	152 (93.2%)

Malignancies	3 (1.8%)	149 (91.4%)

Sufficient hepatitis B immunisation	153 (93.9%)	9 (5.5%)

Ever received BCG (tuberculosis) immunisation	128 (78.5%)	31 (19.0%)

Smoking	17 (10.4%)	145 (89.0%)

Cut-resistant gloves available at workplace	99 (60.7%)	60 (36.8%)

Regular personal use of cut-resistant gloves at dissections/autopsies	39 (23.9%)	108 (66.3%)

Extraction of air in the dissection room considered sufficient	94 (57.7%)	66 (40.5%)


Method Label	Method Description	Library used within R statistical software	Number of iterations

CC	Complete case analysis: Analyses only cases with complete data for all covariates		-

SI	Single imputation performed using PMM	'pmm' function in 'mice'	20

MI-NORM	Multiple imputation (MI) using data augmentation approach [31] with a multivariate normal assumption for all variables	'norm' [41]	100

MI-MIX	MI using data augmentation approach using a general location model	'mix' [42]	100

MI-MIX-no truncating	MI using data augmentation approach using a general location model, but imputed values are not truncated to within plausible range	'mix' [42]	100

MI-MICE	MI using regression switching imputation [9]. Linear model are used for continuous covariates and logistic model for binary covariates and dummy variables for categorical covariates	'mice' [43]	20

MI-MICE-PMM	MI using MICE with PMM	'pmm' function in 'mice' [43]	20

MI-MICE-PMM-no transformation	MI using MICE with PMM without transforming the incomplete covariates	'pmm' function in 'mice' [43]	20

MI-Aregimpute	MI using flexible additive imputation models [20] with PMM	'aregImpute' function in 'Hmisc' [44]	1


Case No.	Age(yrs)	FIGO score	AP	Interval time (mons)	Pretreatment serum β-hCG level	Site of metastases	Chemotherapy	Cause of death

1	53	15	Abortion	180	99000.0	Lung/brain/kidney	Not done	Brain hemorrhage, respiratory failure

2	30	21	Abortion	10	906720.0	Lung/brain/liver/kidney	Not done	Septic shock

3	31	8	Mole	32	80.0	Lung/brain	5-FU*1d	Brain herniation

4	25	12	Mole	27	57380.0	Lung/brain	EMA*1	Brain herniation

5	32	12	Term	6	200000.0	Lung/brain/kidney	FAEV*2d	Respiratory failure, cardiac arrest

6	36	13	Mole	56	9306.0	Lung/brain/bladder	FAEV*1d	Multiple organ failure

7	26	15	Term	3	60436.5	Lung/brain	FAEV*3d	Brain stem hemorrhage

8a	33	17	Mole	36	2400.0	Lung/brain	FAEV*4d	Brain herniation

Site of metastases	Chemotherapy	Cause of death

Lung/brain/kidney	Not done	Brain hemorrhage, respiratory failure

Lung/brain/liver/kidney	Not done	Septic shock

Lung/brain	5-FU*1d	Brain herniation

Lung/brain	EMA*1	Brain herniation

Lung/brain/kidney	FAEV*2d	Respiratory failure, cardiac arrest

Lung/brain/bladder	FAEV*1d	Multiple organ failure

Lung/brain	FAEV*3d	Brain stem hemorrhage

Lung/brain	FAEV*4d	Brain herniation


Characteristics	Antenatal care utilization (< 4 times and ≥ 4 times)

	BivariateOR (95% CI)	MultivariateOR (95% CI)

Distance to health facility

> 30 min	1	1

≤ 30 min	1.69 (1.39-2.05)*	1.44 (1.18-1.77)*


Organism	BlastX threshold

Arabidopsis (31,921)	1e-5

	1e-10

	1e-20

Arabidopsis with transcript evidence (22,032)	1e-5

	1e-10

	1e-20

Populus (45,555)	1e-5

	1e-10

	1e-20

Oryza (66,710)	1e-5

	1e-10

	1e-20


DATA CATEGORY

Counter IDIN

Station

County

City

Route

Mile point

AADT 2009

AADT 2008

AADT 2007

AADT 2006

AADT 2005

AADT 2004

AADT 2003

AADT 2002

AADT 2001

K

D

TDHV

TADT

Heavy

Functional Class


Clinical features

Number of patients	13

Women/men	7/6

Age (years), mean ± SD	52.02 ± 19.01

Triggering factor

 AOSD flare, number (%)	13 (100)

 Lymphoma, number (%)	0

 Infectious disease, number (%)	0

Laboratory features

 WBC (103/mL), mean ± SD	3.28 ± 1.36

 RBC (103/mL), mean ± SD	3.31 ± 0.69

 HB (gr/dL), mean ± SD	9.19 ± 2.05

 PLT (103/mL), mean ± SD	55.52 ± 46.54

 Serum Ferritin (ng/mL), mean ± SD	4362.15 ± 7569.70

 ESR (mm/hour), mean ± SD	71.23 ± 30.19

 CRP (mg/L), mean ± SD	74.76 ± 46.92

 Triglycerides (mg/dL), mean ± SD	183.12 ± 69.33

 ASAT (IU/L), mean ± SD	74.59 ± 41.89

 ALAT (IU/L), mean ± SD	129.98 ± 91.21

Treatments

 High dosage steroid pulses, number (%)	13 (100)

 Immunosuppressive drugs, number (%)	7 (53.84)

 Cyclosporine A, number (%)	5 (38.46)

 Methotrexate, number (%)	2 (15.38)

 Etoposide	0

 Biologic drugs	2 (15.38)

Deaths, number (%)	10 (76.92)

Number of relapses in MAS-survivors patients, mean ± SD	2.66 ± 1.69

Clinical features

Number of patients	13

Women/men	7/6

Age (years), mean ± SD	52.02 ± 19.01

Triggering factor

AOSD flare, number (%)	13 (100)

Lymphoma, number (%)	0

Infectious disease, number (%)	0

Laboratory features

WBC (103/mL), mean ± SD	3.28 ± 1.36

RBC (103/mL),	3.31 ± 0

 mean ± SD	.69

HB (gr/dL), mean ± SD	9.19 ± 2.05

PLT (103/mL), mean ± SD	55.52 ± 46.54

Serum Ferritin (ng/mL), mean ± SD	4362.15 ± 7569.70

ESR (mm/hour), mean ± SD	71.23 ± 30.19

CRP (mg/L), mean ± SD	74.76 ± 46.92

Triglycerides (mg/dL), mean ± SD	183.12 ± 69.33

ASAT (IU/L), mean ± SD	74.59 ± 41.89

ALAT (IU/L), mean ± SD	129.98 ± 91.21

Treatments

High dosage steroid pulses, number (%)	13 (100)

Immunosuppressive drugs, number (%)	7 (53.84)

Cyclosporine A, number (%)	5 (38.46)

Methotrexate, number (%)	2 (15.38)

Etoposide	0

Biologic drugs	2 (15.38)

Deaths, number (%)	10 (76.92)

Number of relapses in MAS-survivors patients, mean ± SD	2.66 ± 1.69


Section	Conventional1	Enzymatic

	%	(US$ × 100)	%	(US$ × 100)

Grain handling	8.2	6,500	8.7	6,500

Steeping (or pretreatment)	22.3	17,700	10.7	8,000


Domain	Scale/items	Parent-report	Self-report

Sexual socialization	Friendship skills of child	5 items	5 items

	Social acceptance by peers	3 items	6 items

	Romantic ability of child	-	3 items

	Openness about intimacy	4 items	3 items

	Adequate dealing with boundaries	8 items	-

Sexual selfhood	Bodily perception	3 items	6 items

	Self-esteem	-	12 items

	Perceived social competence	-	12 items

	Sexual knowledge of the child according to parent	9 items	-

Sexual behavior	Separate items on age or context appropriate behaviors, intimate experiences including age of onset and sexual orientation	33 items	41 items


Species	Ratio Gavage/i.p.	Mean Ratio

G. pacificus	>800, >1000, >340	>713

G. honu	395, 500	448

G. australes	54, 108, 80, 94, 126, 79, 100	92

G. cheloniae	369, 170	270

G. carpenteri	>16	-

F. paulensis	>63	-

G. polynesiensis	1.7	-


Up-regulated miRNAs	Down-regulated miRNAs

mmu-miR-2137	mmu-miR-1199-3p

mmu-miR-5131	mmu-miR-218-5p

mmu-miR-680	mmu-miR-7a-5p

mmu-miR-5130	mmu-miR-374c-5p

mmu-miR-144	mmu-miR-449c-5p

mmu-miR-486	mmu-miR-450a-2-3p

mmu-miR-711	mmu-miR-696

mmu-miR-449a

mmu-miR-193

mmu-miR-34c-5p

mmu-miR-2861

mmu-miR-211-3p

mmu-miR-763

mmu-miR-128-2-5p

mmu-miR-542-5p

mmu-miR-3473

mmu-miR-511-3p

mmu-miR-34c-5p

mmu-miR-143-5p

mmu-miR-5115

Up-regulated miRNAs	Down-regulated miRNAs

mmu-miR-144	mmu-miR-449c-5p

mmu-miR-486	mmu-miR-450a-2-3p

mmu-miR-711	mmu-miR-696

mmu-miR-449a

mmu-miR-193

mmu-miR-34c-5p

mmu-miR-2861

mmu-miR-211-3p

mmu-miR-763

mmu-miR-128-2-5p

mmu-miR-542-5p

mmu-miR-3473

mmu-miR-511-3p

mmu-miR-34c-5p

mmu-miR-143-5p

mmu-miR-5115


Data source	Exhaustive search	KL1LR

		# of GO terms (# in union)	AUC	# of GO terms (# in union)	AUC	NCG

Protein-protein interactions	OPHID	192		0.82	201		0.89	83

Protein domain	Interpro	522	(697)	0.87	408	(518)	0.89	266

	Pfam	600		0.86	311		0.89	210

Phenotype	MGI	213		0.87	346		0.90	129

Phylogenetic profile	BioMart	33	(95)	0.83	59	(166)	0.88	4

	Inparanoid	70		0.84	124		0.88	22

Disease	OMIM	41		0.85	32		0.88	3

Gene expression	Zhang et al.	28		0.81	147		0.90	10

	Su et al.	21	(55)	0.82	158	(309)	0.89	8

	Sage et al.	16		0.83	113		0.90	7


 Criterion	Score

No	Yes

Tortuous vessels	0	1

Large vessels	0	1

Leakage	0	1

Defective flux	0	1


BMI classes	Mean	95% C.I	N

Normal Weight	21.7	20.8–22.6	84

Overweight	19.1	18.3–19.8	123

Obese Class I	18.2	17.3–19.1	77

Obese Class II	17.4	16.3–18.7	37

Obese Class III	17.0	15.9–18.1	59

BMI classes		95% C.I

Normal Weight	21.7	20.8–22.6	84

Overweight	19.1	18.3–19.8	123

Obese Class I	18.2	17.3–19.1	77

Obese Class II	17.4	16.3–18.7	37

Obese Class III	17.0	15.9–18.1	59


	Patients with IBS

(n = 89)

Age in years, mean ± SD	45.7 ± 12.9

Sex, male/female	47/42

BMI, kg/m2	22.1 ± 5.8

Anxiety, mean ± SD	5.17 ± 3.16

Depression, mean ± SD	5.52 ± 3.30

LES	40.0 (11.0–75.0)


Variables	Overall survival(RR, 95% CI)	p	Disease-specific survival(RR, 95% CI))	p	Disease-free survival(RR, 95% CI)	p	Loco-regional control(RR, 95% CI)	p	Distant metastasis-free survival(RR, 95% CI)	p

GTVprn (13 ml)	2.92, 1.22-6.98	0.02	4.10, 1.06-15.97	0.04	4.81, 1.73-13.36	< 0.01	16.83, 1.48-190.78	0.02	2.50, 0.84-7.43	0.10


Characteristics	n	P-valuea,b	Hazard ratioa,b	95% CIa,b

Age

< 20	18 (82%)

> 20	4 (18%)	0.06	0.16	2.3 × 10−10–1.3

Median	13

Gender

Male	15 (68%)	0.05	0.20	1.9 × 10−10–1.2

Female	7 (32%)

Tumor volume (cm3)

Median	1,476	0.40	0.48	0.04–3.0

Range	85–10,590

Tumor surface (cm2)

Median	19.2	0.43	0.50	0.02–3.3

Range	3.2–57.7

Pattern on MRI

Concentric	19 (86%)	0.72	0.47	0.10–2.1

Longitudinal	3 (14%)

Histologic response

Good	12 (54%)	–	–	–

Poor	10 (46%)	–	–	–

Pathologic subtype

Osteoblastic	10 (46%)	–	–	–

Chondroblastic	6 (27%)	–	–	–

Fibroblastic	4 (18%)	–	–	–

Other	2 (9%)	–	–	–

Location

Distal femur	22 (100%)	–	–	–

Metastatic disease

No	22 (100%)	–	–	–

Characteristics

Age

< 20

> 20

Median

Gender

Male

Female

Tumor volume (cm3)

Median

Range

Tumor surface (cm2)

Median

Range

Pattern on MRI

Concentric

Longitudinal

Histologic response

Good

Poor

Pathologic subtype

Osteoblastic

Chondroblastic

Fibroblastic

Other

Location

Distal femur

Metastatic disease

No


Date	Advance	Applications

1670s	Microscope invented by Leeuwenhoek	Visualize bacteria, protozoa

1850s	Puerperal fever identified as infectious and interventions implemented by Semmelweis [23]	Hospital infection control motivated by growing understanding of microbial etiology

1864	Cholera transmission by water proven by Snow	Risk factor (mode of transmission) and prevention measure for specific infectious syndrome

1890s	Proof of parasitic origin (Grassi) and mosquito transmission (Ross) of malaria	Vector control

1890s	Identification of microbial etiologies for tuberculosis, anthrax, and so on; Koch’s postulates	Targeted diagnostics, therapeutics, and move from syndromic diagnosis to pathogen identification

1900-1930s	Discovery of filterable animal viruses [24]	Influenza etiology settled (previously thought bacterial) [25]

1910s-1950s	Phenotypic subspecies taxonomy: serotyping [26,27], phage typing [28]	Association of particular types with prognosis [27,29], drug resistance

1944	Discovery of DNA as the genetic material [30]	Basis for genotyping tools for molecular epidemiology

1970	Restriction enzymes [31]	Basis for restriction fragment length polymorphism approaches, including pulsed field gel electrophoresis

1975-1985	Sanger DNA sequencing [32], PCR [33]	Basis for variable number tandem repeat (VNTR) and multilocus sequence typing (MLST) approaches to characterize microbes and their genetic relatedness

2000s-now	High-throughput rapid sequencing technologies	Microbial genome sequencing


Conditions	Biological Process	FDRp-value	Molecular Function	FDRp-value

Control	response to abiotic or biotic stimulus	2.8e-19	transcription factor activity	3.4e-04

	response to stress	1.6e-13	other enzyme activity	2.1e-03

	other biological processes	7.7e-10	other molecular functions	4.5e-02

Cold	response to stress	4.9e-08	transcription factor activity	1.7e-07

	other biological processes	1.3e-07	receptor binding or activity	3.8e-03

	response to abiotic or biotic stimulus	8.1e-06	kinase activity	2.9e-02

	transcription	3.3e-04

	signal transduction	3.2e-03

Genotoxic	response to abiotic or biotic stimulus	2.9e-20	kinase activity	7.6e-06

	response to stress	3.8e-16	transcription factor activity	8.9e-04

	other biological processes	1.8e-11	transferase activity	1.7e-03

	signal transduction	7.3e-03	transporter activity	1.4e-02

Osmotic	response to stress	1.4e-16	transferase activity	7.0e-04

	response to abiotic or biotic stimulus	1.4e-14	kinase activity	1.4e-03

	other biological processes	1.3e-08	transcription factor activity	1.3e-02

	signal transduction	1.3e-02	other molecular functions	4.3e-02

Salt	response to abiotic or biotic stimulus	3.0e-12	structural molecule activity	1.1e-13

	response to stress	6.0e-07	transferase activity	2.3e-03

	other biological processes	3.3e-03	other enzyme activity	2.4e-02

UV-B	response to abiotic or biotic stimulus	3.1e-12	transferase activity	1.3e-02

	response to stress	2.3e-11	kinase activity	1.4e-02

	other biological processes	1.6e-08

Wounding	response to abiotic or biotic stimulus	1.4e-17	other enzyme activity	6.3e-06

	response to stress	1.0e-15	transferase activity	2.1e-03

	other biological processes	1.1e-10	transcription factor activity	2.1e-03

	other metabolic processes	4.7e-02	hydrolase activity	1.2e-02

			transporter activity	4.1e-02

Drought	response to abiotic or biotic stimulus	2.8e-19	structural molecule activity	7.9e-18

	response to stress	6.0e-19	transferase activity	6.7e-05

	other biological processes	6.4e-10	other enzyme activity	3.8e-04

	other metabolic processes	1.8e-02

Heat	other biological processes	7.0e-12	transferase activity	9.3e-04

	response to abiotic or biotic stimulus	7.7e-10	other enzyme activity	2.1e-03

	response to stress	3.4e-08	hydrolase activity	3.1e-02

	electron transport or energy pathways	9.5e-03

Oxidative	response to abiotic or biotic stimulus	7.3e-17	transcription factor activity	2.2e-03

	other biological processes	6.5e-14	other enzyme activity	5.7e-03

	response to stress	7.7e-10	kinase activity	1.4e-02

			transferase activity	1.6e-02

Conditions	Biological Process	FDRp-value	Molecular Function	FDRp-value

	response to stress	6.0e-07	transferase activity	2.3e-03

	other biological processes	3.3e-03	other enzyme activity	2.4e-02

UV-B	response to abiotic or biotic stimulus	3.1e-12	transferase activity	1.3e-02

	response to stress	2.3e-11	kinase activity	1.4e-02

	other biological processes	1.6e-08

Wounding	response to abiotic or biotic stimulus	1.4e-17	other enzyme activity	6.3e-06

	response to stress	1.0e-15	transferase activity	2.1e-03

	other biological processes	1.1e-10	transcription factor activity	2.1e-03

	other metabolic processes	4.7e-02	hydrolase activity	1.2e-02

			transporter activity	4.1e-02

Drought	response to abiotic or biotic stimulus	2.8e-19	structural molecule activity	7.9e-18

	response to stress	6.0e-19	transferase activity	6.7e-05

	other biological processes	6.4e-10	other enzyme activity	3.8e-04

	other metabolic processes	1.8e-02

Heat	other biological processes	7.0e-12	transferase activity	9.3e-04

	response to abiotic or biotic stimulus	7.7e-10	other enzyme activity	2.1e-03

	response to stress	3.4e-08	hydrolase activity	3.1e-02

	electron transport or energy pathways	9.5e-03

Oxidative	response to abiotic or biotic stimulus	7.3e-17	transcription factor activity	2.2e-03

	other biological processes	6.5e-14	other enzyme activity	5.7e-03

	response to stress	7.7e-10	kinase activity	1.4e-02

			transferase activity	1.6e-02


	Did not require ICU(n = 249)	Required ICU (severe)(n = 18)	Pb value

N (%)	N (%)

Any medical risk factor a	115 (46.2)	11 (61.1)	.22

Influenza B strain	47 (19.0)	7 (38.9)	.04

Iron‐deficient anaemia	21 (8.4)	5 (27.8)	.01

Food allergy	6 (2.4)	2 (11.1)	.09

Proportion less than 2 y of age 	150 (60.2)	14 (77.8)	.14

Antiviral prescribed	34 (13.7)	2 (11.8)	.82

Antibiotic prescribed	121 (48.8)	9 (52.9)	.74

Co‐infection identified	99 (39.8)	8 (47.1)	.55

	Did not require ICU(n = 249)	Required ICU (severe)(n = 18)	Pb value

N (%)	N (%)

Proportion less than 2 y of age	150 (60.2)	14 (77.8)	.14

Antiviral prescribed	34 (13.7)	2 (11.8)	.82

Antibiotic prescribed	121 (48.8)	9 (52.9)	.74

Co‐infection identified	99 (39.8)	8 (47.1)	.55


Baseline characteristics

Sex	Female

Male

Age (years)	<25

	25–64

	≥65

HIV-Status	Negative

	Positive

	Unknown

Type of TB	New SS+

	Retreatment

Place of treatment	CNHP-P

	DOT clinic


Explanatory variable	Coefficient ± Standar Error	P

Body Fat at follow-up equation, kg

 Leisure time physical activity at follow-up, METs/wk	−0.215 ± 0.091	0.019

 Calorie Intake at follow-up, 100 kcal	0.328 ± 0.142	0.021

 Age at follow-up	0.115 ± 0.036	0.001

 Height at follow-up	0.520 ± 0.092	< 0.001

 Constant	28.399 ± 0.425	< 0.001

Leisure time physical activity at follow-up equation, METs/wk

 Body fat at follow-up, kg	1.059 ± 0.456	0.020

 Depression score at follow-up, CES-D*	−0.191 ± 0.095	0.045

 Age at follow-up	−0.025 ± 0.071	0.722

 Constant	−30.038 ± 12.750	0.018

Calorie Intake at follow-up equation, 100 kcal

 Body fat at follow-up, kg	−0.341 ± 0.183	0.063

 Depression score at follow-up, CES-D*	0.188 ± 0.048	< 0.001

 Age at follow-up	−0.067 ± 0.035	0.057

 Constant	9.630 ± 5.285	0.068

Error Covariances

 Calorie intake with physical activity	−26.882 ± 20.302	0.185

Explanatory variable	Coefficient ± Standar Error

Body Fat at follow-up equation, kg

Leisure time physical activity at follow-up, METs/wk	−0.215 ± 0.091

Calorie Intake at follow-up, 100 kcal	0.328 ± 0.142

Age at follow-up	0.115 ± 0.036

Height at follow-up	0.520 ± 0.092

Constant	28.399 ± 0.425

Leisure time physical activity at follow-up equation, METs/wk

Body fat at follow-up, kg	1.059 ± 0.456

Depression score at follow-up, CES-D*	−0.191 ± 0.095

Age at follow-up	−0.025 ± 0.071

Constant	−30.038 ± 12.750

Calorie Intake at follow-up equation, 100 kcal

Body fat at follow-up, kg	−0.341 ± 0.183

Depression score at follow-up, CES-D*	0.188 ± 0.048

Age at follow-up	−0.067 ± 0.035

Constant	9.630 ± 5.285

Error Covariances

Calorie intake with physical activity	−26.882 ± 20.302

P

Body Fat at follow-up equation, kg

0.019

0.021

0.001

< 0.001

< 0.001

Leisure time physical activity at follow-up equation, METs/wk

0.020

0.045

0.722

0.018

Calorie Intake at follow-up equation, 100 kcal

0.063

< 0.001

0.057

0.068

Error Covariances

0.185


Brain regions	 	Voxels	X (MNI)	Y (MNI)	Z (MNI)	T value

High BrAC group < control

 Superior frontal gyrus	R	750	15	21	57	−4.6134

R	39	12	39	−24	−3.7952

 Inferior frontal gyrus	R 	37	54	21	18	−4.4388

 Hippocampal gyrus	R	39	18	−6	−33	−4.6794

 Inferior temporal gyrus	R	30	33	9	−45	−4.2946

High BrAC group > control

 Middle frontal gyrus	L	100	−27	45	3	4.7207

R	42	12	−21	60	6.4199

 Basal ganglia	L	468	−27	12	−3	5.7696

 Cerebellum 	R	114	9	48	−24	6.8909

 Internal capsule	R	39	9	0	6	3.9489

Superior frontal gyrus	R	39	12	39	−24	−3.7952

Inferior frontal gyrus	R	37	54	21	18	−4.4388

Hippocampal gyrus	R	39	18	−6	−33	−4.6794

Inferior temporal gyrus	R	30	33	9	−45	−4.2946

High BrAC group > control

Middle frontal gyrus	L	100	−27	45	3	4.7207

R	42	12	−21	60	6.4199

Basal ganglia	L	468	−27	12	−3	5.7696

Cerebellum	R	114	9	48	−24	6.8909

Internal capsule	R	39	9	0	6	3.9489


Gene	Acc. No	Primer sequence (5′ to 3′)

Pparg (mouse)	NM_001127330	F: GACCACTCGCATTCCTTT

 	 	R: CCACAGACTCGGCACTCA

Fabp4 (mouse)	NM_024406	F: AAATCACCGCAGACGACA

 	 	R: CACATTCCACCACCAGCT

Runx2 (mouse)	NM_001146038	F: ACTTCCTGTGCTCCGTGCTG

 	 	R: TCGTTGAACCTGGCTACTTGG

Osterix (mouse)	NM_130458	F: ACCAGGTCCAGGCAACAC

 	 	R: GCAAAGTCAGATGGGTAAGTAG

Tmem64 (mouse)	NM_181401	F: AGGAAGCGGCCTGAAGGT

 	 	R: GAAGGAAGAGCCACTGGGAT

β-actin (mouse)	NM_007393	F: CTGTCCCTGTATGCCTCTG

 	 	R: TGATGTCACGCACGATTT

Gene	Acc. No

Pparg (mouse)	NM_001127330

Fabp4 (mouse)	NM_024406

Runx2 (mouse)	NM_001146038

Osterix (mouse)	NM_130458

Tmem64 (mouse)	NM_181401

β-actin (mouse)	NM_007393

Primer sequence (5′ to 3′)

F: GACCACTCGCATTCCTTT

R: CCACAGACTCGGCACTCA

F: AAATCACCGCAGACGACA

R: CACATTCCACCACCAGCT

F: ACTTCCTGTGCTCCGTGCTG

R: TCGTTGAACCTGGCTACTTGG

F: ACCAGGTCCAGGCAACAC

R: GCAAAGTCAGATGGGTAAGTAG

F: AGGAAGCGGCCTGAAGGT

R: GAAGGAAGAGCCACTGGGAT

F: CTGTCCCTGTATGCCTCTG

R: TGATGTCACGCACGATTT


	Girls	Boys

Goodness-of-fit statistics	1-factor model	2- factor model	1-factor model

χ2	8.13	4.41	4.44

df	5	4	5

p	.15	.35	.49

RMSEA	.028	.018	.00

CFI	.98	.99	1.00

TLI	.97	.98	1.02

r		.61


			First outbreak (October 2013)		Second outbreak (July 2014)

Water temperature: 23 °C	Water temperature: 26 °C

Cage	Date stocked	Age at stocking (months)	Average weight at first outbreak (g)	Cumulative mortality (%)	Average weight at second outbreak (g)	Cumulative mortality (%)

1	April 2012	2	323	4,82	336	4,86

2	April 2012	2	319	5,30	440	5,3

3	July 2012	5	292	4,76	441	4,76

4	April 2013	2	84	2,23	274	2,23

			First outbreak (October 2013)		Second outbreak (July 2014)

Water temperature: 23 °C	Water temperature: 26 °C

Cage	Date stocked	Age at stocking (months)	Average weight at first outbreak (g)	Cumulative mortality (%)	Average weight at second outbreak (g)

1	April 2012	2	323	4,82	336

2	April 2012	2	319	5,30	440

3	July 2012	5	292	4,76	441

4	April 2013	2	84	2,23	274

Water temperature: 26 °C

Cumulative mortality (%)

4,86

5,3

4,76

2,23


Treatment	Days from transplant to initial bolting (d)	Days from transplant to 50% bolting (d)	Bolting rate by 30 April (%)

	2011	2012	2011	2012	2011	2012

Grand mean	128.4	139.7	140.5	-	39.7	16.0


Brain region	BA	Cluster sizes	t-value	P value	Peak MNI coodinate

(voxels)	(Corr.)	X	Y	Z

R medial prefrontal cortex	8	12	6.02	<.05	9	27	57

R middle frontal gyrus	9	211	10.87	<.05	3	48	21

L middle temporal gyrus	21	14	−5.49	<.05	−66	−54	3

R superior temporal gyrus	38	12	−5.59	<.05	54	12	−18

L primary somatosensory cortex	2	19	−3.88	<.05	−60	−21	42

R inferior parietal lobule	40	10	−10.94	<.05	66	−36	21

L parahippocampal gyrus	―	11	−5.62	<.05	−9	−3	−21

R parahippocampal gyrus	35	29	9.51	<.05	30	−6	−21

L anterior cingulate cortex	32	12	−4.74	<.05	−6	21	39

R precuneus	7	14	4.70	<.05	18	−66	33

R insula	13	10	5.47	<.05	39	0	18

R cerebellar tonsil	―	13	5.30	<.05	9	−60	−48

Brain region

R medial prefrontal cortex

R middle frontal gyrus

L middle temporal gyrus

R superior temporal gyrus

L primary somatosensory cortex

R inferior parietal lobule

L parahippocampal gyrus

R parahippocampal gyrus

L anterior cingulate cortex

R precuneus

R insula

R cerebellar tonsil


Category	Treatment adherence barriers

Stigma related factors	▪ Fear of disclosure of child’s status to the teachers and family members by parents

▪ Segregation by teachers and other children

Lack of supportive environment at home	▪ Inadequate support from parents

➢ Parents move to farming areas without one to follow up on child’s treatment schedule

➢ Men do not provide enough treatment adherence support

➢ Extended family members do not provide support

Lack of supportive environment from school	▪ Teachers do not provide adequate support to children on ART

Health service delivery factors	▪ Lack of child friendly counseling services

▪ Inconvenient treatment schedule

▪ Longevity of treatment

Patient factor	▪ Forgetfulness

▪ Feeling better

Category	Treatment adherence barriers

Stigma related factors	▪ Fear of disclosure of child’s status to the teachers and family members by parents

▪ Segregation by teachers and other children

Lack of s	▪ Inadequate support from pare

upportive environment at home	nts

➢ Parents move to farming areas without one to follow up on child’s treatment schedule

➢ Men do not provide enough treatment adherence support

➢ Extended family members do not provide support

Lack of supportive environment from school	▪ Teachers do not provide adequate support to children on ART

Health service delivery factors	▪ Lack of child friendly counseling services

▪ Inconvenient treatment schedule

▪ Longevity of treatment

Patient factor	▪ Forgetfulness

▪ Feeling better


	Factor

1

Me siento cansado y desanimado cuando me levanto por las mañanas	0.612

Mis músculos están tensos y doloridos	0.650

Tengo ataques de pánico	0.388

Rechino los dientes o aprieto la mandíbula	0.342

Tengo problemas de diarrea o estreñimiento	0.400

Necesito ayuda pare realizar mis actividades diarias	0.476

Soy sensible a la luz brillante	0.440

Me canso fácilmente cuando estoy físicamente activo	0.724

Siento dolor en todo mi cuerpo	0.582

Tengo dolores de cabeza	416

Tengo molestia en mi vejiga o sensación de quemazón al orinar	0.294

No duermo bien	0.504

Tengo dificultad para concentrarme	0.436

Tengo problemas en la piel como resequedad, picor o sarpullido	0.299

El estrés hace que mis síntomas físicos empeoren	0.587

Me siento triste o deprimido	0.621

Me siento con poca energía	0.718

Tengo tensión muscular en mi cuello y hombros	0.555

Tengo dolor en mi mandíbula	0.426

Algunos olores, como perfumes, me hacen sentir náuseas.	0.269

Tengo que orinar frecuentemente	0.276

Mis piernas se sienten incómodas e inquietas cuando intento dormir por la noche	0.476

Tengo dificultad para recordar cosas	0.482

Sufrí algún trauma cuando era niño (a)	0.120

Tengo dolor en mi zona pélvica	0.289

	Factor

1

Tengo dificultad para concentrarme	0.436

Tengo problemas en la piel como resequedad, picor o sarpullido	0.299

El estrés hace que mis síntomas físicos empeoren	0.587

Me siento triste o deprimido	0.621

Me siento con poca energía	0.718

Tengo tensión muscular en mi cuello y hombros	0.555

Tengo dolor en mi mandíbula	0.426

Algunos olores, como perfumes, me hacen sentir náuseas.	0.269

Tengo que orinar frecuentemente	0.276

Mis piernas se sienten incómodas e inquietas cuando intento dormir por la noche	0.476

Tengo dificultad para recordar cosas	0.482

Sufrí algún trauma cuando era niño (a)	0.120

Tengo dolor en mi zona pélvica	0.289


Symbol	2 Days vs. Ctr	4 Days vs. Ctr	7 Days vs. Ctr

P-Value	Fold Change	P-Value	Fold Change	P-Value	Fold Change

ANKRD50	2.82 × 10−2	−1.323	2.32 × 10−6	−2.191	2.35 × 10−4	−1.749

ANKRD36B	4.65 × 10−3	−2.292	1.85 × 10−3	−2.546	9.24 × 10−3	−1.979

C9orf3	7.91 × 10−4	−3.622	5.04 × 10−4	−3.860	6.56 × 10−2	−1.938


Patient Safety Culture Composite	Definition: The extent to which....	Number of Survey Items

1. Communication openness	Staff will freely speak up if they see something that may negatively affect patient care, and feel free to question those with more authority	3

2. Feedback & communication about error	Staff are informed about errors that happen, given feedback about changes put into place based on event reports, and discuss ways to prevent errors	3

3. Frequency of events reported	Mistakes of the following types are reported:1) mistakes caught and corrected before affecting the patient, 2) mistakes with no potential to harm the patient, and 3) mistakes that could harm the patient, but do not	3

4. Handoffs & transitions	Important patient care information is transferred across hospital units and during shift changes	4

5. Management support for patient safety	Hospital management provides a work climate that promotes patient safety and shows that patient safety is a top priority	3

6. Nonpunitive response to error	Staff feel that their mistakes are not held against them, and mistakes are not kept in their personnel file	3

7. Organizational learning--Continuous improvement	Mistakes have led to positive changes and changes are evaluated for their effectiveness	3

8. Overall perceptions of patient safety	Procedures and systems are good at preventing errors and there is a lack of patient safety problems	4

9. Staffing	There are enough staff to handle the workload and work hours are appropriate to provide the best care for patients	4

10. Supervisor/manager expectations and actions promoting safety	Supervisors/managers consider staff suggestions for improving patient safety, praise staff for following patient safety procedures, and do not overlook patient safety problems	4

11. Teamwork across units	Hospital units cooperate and coordinate with one another to provide the best care for patients	4

12. Teamwork within units	Staff support one another, treat each other with respect, and work together as a team	4


Oligonucleotide	Sequence

NUCKS F (forward)	5'-AATTCACAGGAAGATAGTGAGG-3'

NUCKS R (reverse)	5'-TCACTGTAG CCTTTAGTCTGGG-3'

GAPDH forward	5'-ATGGGGAAGGTGAAGGTCGGAGTC-3'

GAPDH reverse	5'-GAACATGGGGGCGTCAGCAGAG-3'

NUCKS Fq (forward, real-time PCR)	5'-TCTGATGATGCAGATGAAGATTA-3'

NUCKS Rq (reverse, real-time PCR)	5'-CTGCTGAGTGAGAATCATCC-3'

NUCKS FL probe	5'-TCTTGGTCTTCACATCTTTGTCTTCT-FL-3'

NUCKS LC probe	5'-LC640-AGTCCTCACTATCTTCCTGTGAATTCTTT-3'


Characteristics of the partner at the first sexual relation	Sex (%)

Women	Men

Type of relationship

Namorado (steady boyfriend/girlfriend)	86	45

Husband/wife/living together	4	1

Eventual partner	9	48

Prostitute	—	5

Was it also the partner's first sexual relation?

Yes	14	37

No	83	57

Do not know	3	6

Age difference between the interviewee and the partner

The partner is younger	2	10

Same age (±1 year)	24	52

The partner is older (2–4 years)	36	24

The partner is much older (5 years and more)	38	15

The partner was in school

Yes	50	76

No	50	24

Characteristics of the partner at the first sexual relation	Sex (%)

Women	Men

Yes	50	76

No	50	24


Demographic	Number (%)

Gender

Male	64 (43.2)

Female	84 (56.8)

Marital status

Single	57 (38.5)

Married	44 (29.7)

Widowed	10 (6.8)

Divorced	36 (24.3)

Unknown	1 (0.7)

Educational level

None	6 (4.1)

Primary	45 (30.4)

Secondary	83 (56.1)

University/post graduate	13 (8.8)

Unknown	1 (0.7)

Diagnosis

Schizophrenia	53 (35.8)

Paranoid Schizophrenia	35 (23.6)

Delusional disorder	10 (6.8)

Bipolar affective disorder (BPAD)	15 (10.1)

Psychotic depression	23 (15.5)

Other (i.e. schizoaffective disorder; non-specified psychosis)	10 (6.8)

Unknown	2 (1.4)

Employment status

Unemployed	68 (45.9)

Employed	39 (26.3)

Homemaker	35 (23.6)

Retired/other	5 (3.4)

Unknown	1 (0.7)


Indices of clinical burden of Sickle Cell Disease	Children

n	%

Duration of care since diagnosis

≤ 6 months	22	9.8

> 6 months	203	90.2

Previous hospitalisation (range = 0–24)

No hospitalisation	16	7.1

Once	32	14.2

Twice	85	37.8

> twice	92	40.9

Previous blood transfusion (range = 0–10)

None	67	29.8

Once	53	23.6

Twice	70	31.1

> twice	35	15.6

Significant bone pain episodes

None	13	5.8

One	41	18.2

Twice	25	11.1

> twice	146	64.9

Indices of clinical burden of Sickle Cell Disease	Children

n	%

Twice	85	37.8

> twice	92	40.9

Previous blood transfusion (range = 0–10)

None	67	29.8

Once	53	23.6

Twice	70	31.1

> twice	35	15.6

Significant bone pain episodes

None	13	5.8

One	41	18.2

Twice	25	11.1

> twice	146	64.9


	(A) 176 drug products	(B) 45 drug products	(C) 162 drug products

Therapeutic group

 A—alimentary tract and metabolism	18	8	17

 B—blood and blood-forming organs	9	3	8

 C—cardiovascular system	20	3	20

 D—dermatologicals	6	3	5

 G—genitourinary system and sex hormones	13	1	13

 H—systemic hormonal preparations, excluding sex hormones and insulins	7	1	6

 J—anti-infectives for systemic use	25	5	23

 L—anti-neoplastic and immunomodulating agents	10	3	10

 M—musculoskeletal system	6	3	6

 N—nervous system	24	8	23

 P—anti-parasitic products, insecticides, and repellents	2	0	1

 R—respiratory system	15	4	10

 S—sensory organs	6	1	6

 V—various	15	2	14

Re-examination dates

 January 2009 to December 2009	45	6	42

 January 2010 to December 2010	44	13	42

 January 2011 to December 2011	30	9	27

 January 2012 to December 2012	21	5	20

 January 2013 to December 2013	19	8	16

 January 2014 to December 2014	17	4	15


Variables	Mean±SD

BMI (Kg/m2)	43.40 ± 20.20

Post-Load PG (mg/dL)	80.00±15.80

SBP (mmHg)	127.60 ± 26.70

DBP (mmHg)	80.00 ± 15.80

FPG (mg/dL)	93.40 ± 19.80

Waist Circumference (CM)	182.84 ± 101.10

Variables

BMI (Kg/m2)

Post-Load PG (mg/dL)

SBP (mmHg)

DBP (mmHg)

FPG (mg/dL)

Waist Circumference (CM)


Indication for surgery	Frequency	Percentage

Bleeding duodenal ulcers not responding to either medical or endoscopic treatment	5	26.3

Gastric malignancy	6	31.6

Gastrointestinal stroma tumour	8	42.1

Indication for surgery	Frequency

Bleeding duodenal ulcers not responding to either medical or endoscopic treatment	5

Gastric malignancy	6

Gastrointestinal stroma tumour	8


Subfamily	Gene identification		Domain organisation	Amino acids

ABCB

 ABCB1	PFE1150w	PfMDR1	(MSD-NBD)2	1419

 ABCB2	PF14_0455	PfMDR2	MSD-NBD	1024

 ABCB3	PF11_0466		MSD-NBD	872

 ABCB4	PFC0125w		MSD-NBD	1365

 ABCB5	PF13_0218		MSD-NBD	925

 ABCB6	PF13_0271		MSD-NBD	1049

 ABCB7	PFL0495c		MSD-NBD	855

ABCC

 ABCC1	PFA0590w	PfMRP1	(MSD-NBD)2	1822

 ABCC2	PFL1410c	PfMRP2	(MSD-NBD)2	2108

ABCE

 ABCE1	MAL13 P1.344		(NBD)2	619

ABCF

 ABCF1	PF11_0225		(NBD)2	815

 ABCF2	pfGCN20PF08_0078		(NBD)2	1419

ABCG

 ABCG1	PF14_0244		NBD-MSD	660

ABCI

 ABCI1	PF14_0133		NBD	347

 ABCI2	PF14_0321		NBD	171

 ABCI3	PFC0875w		MSD-NBD-MSD	3133


Patient	Gene	Varianta	Patient cancer historyb

Discovered cancer gene mutations (163 disease-gene panel)c

BRCA1.60	CHEK2	c.573+1G>A	Breast-47, 49

BRCA1.61	ATM	p.Glu2290⁎	Unaffected-24

BRCA2.7	RAD50	c.3G>A	Breast-49

BRCA2.13	ATM	p.Glu1978⁎	Breast-28, 39, 55; Skin-49

BRCA2.65	CDKN2B	p.Glu35⁎	Melanoma-50

BRCA2.93	CHEK2	p.Gln20⁎	Breast-37, 61; Ovarian-56

Discovered cancer gene mutations (ClinVar)c

BRCA1.48	ERCC3	p.Arg109⁎	Breast-39; Skin-61, 66

BRCA1.73	DLEC1	c.2436-2A>G	Breast-32

BRCA1.74	FANCC	p.Arg548⁎	Breast-42, 53, 55

Patient	Gene

Discovered cancer gene mutations (163 disease-gene panel)c

BRCA1.60	CHEK2

BRCA1.61	ATM

BRCA2.7	RAD50

BRCA2.13	ATM

BRCA2.65	CDKN2B

BRCA2.93	CHEK2

Discovered cancer gene mutations (ClinVar)c

BRCA1.48	ERCC3

BRCA1.73	DLEC1

BRCA1.74	FANCC

Varianta	Patient cancer historyb

Discovered cancer gene mutations (163 disease-gene panel)c

c.573+1G>A	Breast-47, 49

p.Glu2290⁎	Unaffected-24

c.3G>A	Breast-49

p.Glu1978⁎	Breast-28, 39, 55; Skin-49

p.Glu35⁎	Melanoma-50

p.Gln20⁎	Breast-37, 61; Ovarian-56

Discovered cancer gene mutations (ClinVar)c

p.Arg109⁎	Breast-39; Skin-61, 66

c.2436-2A>G	Breast-32

p.Arg548⁎	Breast-42, 53, 55


DPC*	Type	Pathological findings†

		Lung	Inguinal Lymph Nodes	Heart

14	I	Moderate focal/multifocal bronchointerstitial pneumonia (3/3)	Lymphadenopathy (3/3)	Mild multifocal perivascular lymphohistiocytic myocarditis (1/3)

	II	Moderate diffuse/multifocal bronchointerstitial pneumonia (2/3)	Lymphadenopathy (3/3)	Mild multifocal perivascular lymphohistiocytic myocarditis. (3/3)

	Control	No lesions (2/2)	No lesions (2/2)	No lesions (2/2)

21	I	Moderate diffuse interstitial pneumonia (2/2), moderate peribronchiolar and perivascular lymphohistiocytic cuffing (2/2)	Lymphadenopathy (2/2)	Mild multifocal perivascular lymphohistiocytic myocarditis (1/2)

	II	Mild to moderate diffuse interstitial pneumonia (2/2), severe peribronchiolar and perivascular lymphohistiocytic cuffing (1/2)	Lymphadenopathy (2/2)	Very mild multifocal perivascular lymphohistiocytic myocarditis (1/2)

	Control	No lesions (1/1)	No lesions (1/1)	No lesions (1/1)

	Type	gical findings†

		Lung	Inguinal Lymph Nodes	Heart

14	I	Moderate focal/multifocal bronchointerstitial pneumonia (3/3)	Lymphadenopathy (3/3)	Mild multifocal perivascular lymphohistiocytic myocarditis (1/3)

	II	Moderate diffuse/multifocal bronchointerstitial pneumonia (2/3)	Lymphadenopathy (3/3)	Mild multifocal perivascular lymphohistiocytic myocarditis. (3/3)

	Control	No lesions (2/2)	No lesions (2/2)	No lesions (2/2)

21	I	Moderate diffuse interstitial pneumonia (2/2), moderate peribronchiolar and perivascular lymphohistiocytic cuffing (2/2)	Lymphadenopathy (2/2)	Mild multifocal perivascular lymphohistiocytic myocarditis (1/2)

	II	Mild to moderate diffuse interstitial pneumonia (2/2), severe peribronchiolar and perivascular lymphohistiocytic cuffing (1/2)	Lymphadenopathy (2/2)	Very mild multifocal perivascular lymphohistiocytic myocarditis (1/2)

	Control	No lesions (1/1)	No lesions (1/1)	No lesions (1/1)


 	Believes PPM has exposed him/her to hazardous chemicals	Felt he/she was coughing, breathless or wheezing due to something in the air	Believes the industry will affect children born in the future in the community	Believes the industry will expose him/her to hazards if it opens in the future	Worries about getting health problems in the future because of a polluted environment

OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI

Demographic	Distance from PPM	2.747*	1.199-6.295	1.039‡	0.560-1927	1.132‡	0.502-2.554

Presence of a child in the HH	34.769*	1.390-869.96

Respondent completed HS	3.105*	1.394-6.918	 	 	 	 	 	 	2.553*	1.086-6.004

Employment Status	 	 	 	 	0.434‡	0.188-1.004	0.383*	0.167-0.879	0.365*	0.150-0.886

HH health Indicators	Perception of health	0.527‡	0.239-1.162	0.479*	0.261-0.878	0.299*	0.135-0.660	0.237**	0.108-0.517	0.332*	0.149-0.738

Somebody in the HH has one of the conditions (heart, respiratory or skin disease)	1.788‡	0.755-4.237	1.980*	1.031-3.802	2.192‡	0.963-4.990	 	 	2.594*	1.096-6.143

Respiratory symptoms	Coughed phlegm daily for ≥ 2 months, 2 yrs in a row	 	 	2.907*	1.127-7.498

Had an attack of whistling or noisy sound in the chest when breathing	 	 	2.881*	1.402-5.920

Role of Industrial plant	Family depended on industry	 	 	 	 	2.287*	1.001-5.228	2.792*	1.234-6.319

Community benefited from industry	 	 	 	 	 	 	 	 	2.289*	0.997-5.257

Environmental awareness/knowledge	Ever actively looked for environmental health information	 	 	1.883*	1.002-3.537

Willing to participate in environmental campaigns	 	 	2.297‡	0.713-7.396	2.985*	1.031-8.645	 	 	3.127*	1.100-8.888

Main Information source	Friends/relatives	2.553*	1.198-5.438	 	 	0.411*	0.180-0.937	0.451*	0.207-0.981

Church/Community leaders	 	 	 	 	3.148*	1.303-7.602	2.368*	1.090-5.147	2.447*	1.089-5.499

Omnibus Tests of Model Coefficients	Model (Sig.)	<0.001	<0.001	<0.001	<0.001	<0.001

Correctly predicted observations on average	 	85.6%	79.7%	84.6%	86%	84.4%

Environmental awareness/knowledge	Willing to participate in environmental campaigns			2.297‡	0.713-7.396	2.985*	1.031-8.645			3.127*	1.100-8.888

Main Information source	Friends/relatives	2.553*	1.198-5.438			0.411*	0.180-0.937	0.451*	0.207-0.981

Church/Community leaders					3.148*	1.303-7.602	2.368*	1.090-5.147	2.447*	1.089-5.499

Omnibus Tests of Model Coefficients	Model (Sig.)	<0.001	<0.001	<0.001	<0.001	<0.001

Correctly predicted observations on average		85.6%	79.7%	84.6%	86%	84.4%


Hemi	Region	ß	SE	p-value (uncorrected)	FDR-corrected p-value

R	Nucleus accumbens	−0.23	0.058	0.000077	0.0055

L	Inferior parietal cortex	−0.38	0.10	0.00014	0.0055

R	Superior parietal cortex	−0.42	0.12	0.00056	0.011

R	Caudate nucleus	−0.28	0.081	0.00064	0.011

L	Putamen	−0.24	0.071	0.00068	0.011

L	Caudate nucleus	−0.23	0.071	0.0011	0.014

R	Amygdala	−0.21	0.064	0.0012	0.014

L	Supramarginal gyrus	−0.26	0.098	0.0076	0.076

R	Supramarginal gyrus	−0.27	0.10	0.0090	0.076


Outcome	General anaesthesia

Major VTE and VTE-related mortality	4.2%*

(73/1731)

MBE	1.2%

	(27/2311)

MBE/CRBE	4.9%

	(114/2311)


RFB	Mineral Filler Quantity(g)	Mineral Filler A Vg = 0.26	Mineral Filler B Vg = 0.11	Mineral Filler C Vg = 0.19	Mineral Filler D Vg = 0.32

S(g)	F(g)	S/F	F(g)	S(g)	F(g)	S/F	S(g)	F(g)	S/F

5	150	6.8	.2	0.88	.20	0	0	.52	57.60	42.40	36